NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Therapeutic area: Amyotrophic lateral sclerosis
An overview of the submission details for the drug under review is provided in Table 1.
Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disorder characterized by the degeneration of upper motor neurons (UMNs) and lower motor neurons (LMNs).1 Symptoms of ALS are typically first noticed when limb weakness occurs, though the first symptoms can also be bulbar and involve difficulty in speaking or swallowing. Over time, patients lose function in additional regions, such as other limbs and respiratory muscles. Progressive muscle weakness and eventual respiratory failure leads to death.2,3 ALS is a clinically heterogeneous disease in terms of presentation and rate of progression. There is no definitive test for diagnosing ALS, and there can be a long duration from symptom onset to diagnosis. The etiology of the disease is unknown.2 In a Canadian systematic review published in 2009,4 estimates of age-adjusted annual incidence of ALS ranged from 2.0 to 2.4 per 100,000 persons.
There is no cure for ALS. Health Canada–approved treatments for ALS include riluzole and edaravone. Riluzole is an oral medication that has been shown to extend tracheostomy-free survival by 2 months to 3 months in patients with ALS.5 Edaravone, a free radical scavenger thought to prevent oxidative damage to vascular endothelial cells and nerve cells, is currently available as an intravenously administered drug and has been found to slow the rate of decline in motor function.6 According to clinical expert opinion, IV edaravone is typically administered concomitantly with riluzole but had a low uptake at the time of this review in part because of the IV mode of administration and because it is a complex regimen.
This Reimbursement Review report evaluates orally administered edaravone, which is available as an oral suspension of 105 mg of edaravone per 5 mL of suspension. The Health Canada–approved indication is for the treatment of patients with ALS. According to the draft product monograph, the Health Canada–recommended dose of oral edaravone is 105 mg (5 mL) taken orally or via a feeding tube (percutaneous endoscopic gastrostomy or nasogastric tube). The recommended treatment regimen starts with an initial treatment cycle of daily dosing for 14 days followed by a 14-day drug-free period. Subsequent treatment cycles involve daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods. Edaravone oral suspension should be taken in the morning after fasting overnight for at least 8 hours and waiting at least 1 hour before eating or drinking anything except water. For patients who are unable to fast overnight, the required fasting interval can be shortened depending on the type of meal. Patients treated with 60 mg of edaravone injection may be switched to 105 mg (5 mL) edaravone oral suspension using the same dosing frequency. Upon switching to edaravone oral suspension, patients should follow edaravone oral suspension dosing recommendations with regard to food consumption.7 Edaravone injection was recommended for reimbursement for the treatment of ALS by the CADTH Canadian Drug Expert Committee (CDEC) in March 2019, if CDEC-specified conditions were met.6
The information in this section is a summary of the input provided by the patient and clinician groups that responded to CADTH’s call for input and from a clinical expert consulted by CADTH for the purpose of this review.
One patient advocacy group, the ALS Society of Canada, submitted the patient input for this review. The submission was based on an online survey that collected input from 629 patients and caregivers from Ontario and Quebec and on telephone interviews with 7 patients who had experience with oral edaravone.
Respondents indicated that the most severe of ALS symptoms include difficulties with mobility (including walking and standing), gripping or holding things, muscle cramping or twitching, and fatigue caused by muscle exhaustion. These symptoms were also among the most important to control for people living with ALS, in addition to difficulties breathing, speaking, and swallowing. Patients indicated that their social life, travel and hobbies, and family life suffered the most. In addition, caregivers of patients with ALS highlighted a negative impact on emotional and psychological well-being, including pervasive feelings of overwhelming grief and struggles with mental health, including stress, anxiety, helplessness, and hopelessness. Loss of independence was mentioned as touching all aspects of patients’ lives and dramatically impacting caregivers, as patients eventually need help performing all daily tasks. Patients and caregivers reported treatment experience with riluzole and IV edaravone. Slowing disease progression, maintaining ability to participate in daily activities, and increasing survival were identified as the most important benefits from therapy. Access to riluzole and IV edaravone treatments was a problem for some patients. Other difficulties reported with edaravone were mostly related to the IV administration, including patients having to schedule activities of daily living around their infusion schedule and needing to have a port catheter implanted.
The clinical expert consulted by CADTH for the purpose of the review indicated that there is currently no ideal treatment that prevents disease progression. At the time of this review, the only Health Canada–approved disease-modifying treatments for ALS were riluzole and IV edaravone, both showing modest benefits in slowing disease progression. The expert indicated that patients would usually be prescribed riluzole for its clinical benefits and because it is easily administered and well tolerated. Patients meeting the criteria for reimbursement would then be offered IV edaravone as an add-on therapy.
The mainstay of care for patients with ALS consists of symptom management and quality-of-life optimization. The clinical expert highlighted that patients should be diagnosed and followed by an ALS specialist as part of a multidisciplinary care team. The clinical expert noted that current standard of care involves following the patient at regular intervals and monitoring their physical, functional, emotional, and quality-of-life parameters. Medications are titrated appropriate to a patient’s condition and to their goals of care, in a palliative-focused approach.
According to the clinical expert, patients with the greatest need are those patients with preservation of the ability to complete at least 1 of their own activities of daily life. Based on the clinical expert’s experience, it would not be appropriate to recommend that patients would try to (and not) receive sufficient benefit from other treatments before initiating oral edaravone. Requiring the patient to demonstrate that a treatment has failed before introduction of another treatment would subject them to irreversible progression that would otherwise have been slowed had other therapies been given concurrently and would not be reflective of currently available evidence.
According to the clinical expert, the uptake of IV edaravone has so far been low, in part because the IV formulation is invasive and comes with a time-consuming administration schedule. The clinical expert considered that the oral formulation would be a well-received alternative, as many patients choose not to embark on the currently available IV formulation because of the caveats and excessive requirements and constraints related to IV infusion.
One clinician group, the Canadian ALS Research Network (CALS), has provided input, which was in line with the input provided by the clinical expert consulted by CADTH. CALS acknowledged the need for ALS disease-modifying treatment options aiming at slowing disease progression, as well as the need for oral edaravone in clinical practice due to increased accessibility.
The drug program implementation questions were aimed at gaining insight from the clinical expert consulted by CADTH about whether the submitted trials would be sufficient to show bioequivalence between the oral and IV versions of edaravone. The clinical expert consulted by CADTH indicated that there is no reason to think that the efficacy profiles of the 2 versions would differ; however, whether they can be considered to display comparable bioavailability will be assessed by Health Canada during formal review. Both the drug plans and the clinical expert also noted that an oral version of edaravone would be a lot easier for patients to access than its IV formulation, reducing the risk of exposure to unnecessary infusion-associated adverse events (AEs) and decreasing health care system burden related to the IV administration. The clinical expert expects that both edaravone-naive and edaravone-experienced patients would be prescribed treatment with the oral version of the product, expanding the number of patients using the medication. The drug plans questioned the clinical expert regarding the existing prescribing criteria for IV edaravone. The clinical expert highlighted that ALS should be managed by a specialist and a multidisciplinary team. It is the clinical expert’s opinion that there is sufficient access to ALS specialists across the country and that there is no need to expand to family doctors.
To inform on the use of oral edaravone compared to its IV formulation, 2 manufacturer-sponsored studies were included in this review. The single-dose, randomized, open-label study MT-1186-J03 (n = 42)8,9 evaluated the bioequivalence of the oral suspension and IV formulation of edaravone in healthy individuals who identified as Japanese. The study assessed drug concentration (in plasma and urine) of unchanged edaravone, sulphate conjugate, and glucuronide conjugate, as well as various pharmacokinetic parameters, including the area under the plasma concentration–time curve (AUC) and the maximum plasma concentration after administration (Cmax) with the bioequivalence limit (0.80 to 1.25). Oral edaravone was administered as an oral suspension at 105 mg for a single dose.
The multicentre, open-label, single-group study MT-1186-A01 (n = 185)10 evaluated the longer-term safety and tolerability of oral edaravone in patients with ALS living and functioning independently whose first symptom of ALS had occurred within the previous 3 years and who had a baseline forced vital capacity (FVC) greater than or equal to 70%. At the time of this review, the 24-week results were available. Patients received edaravone as a 105 mg oral suspension administered in accordance with the Health Canada–approved regimen. The concomitant use of riluzole was permitted throughout the study.
According to the sponsor’s conclusions, study MT-1186-J03 showed that oral suspension edaravone 105 mg was bioequivalent to an IV formulation of edaravone 60 mg in healthy volunteers who identified as Japanese. In this analysis, oral edaravone had equivalent AUC from zero up to the last quantifiable concentration time point (AUC0-t) and AUC from zero up to infinity with extrapolation of the terminal phase (AUC0-∞) of unchanged edaravone compared to the IV formulation, as both geometric mean ratio and 90% confidence interval (CI) were within the range of 0.80 to 1.25. As for Cmax, the geometric mean ratio and its lower limit at the 90% CI were also within the prespecified limits, while the upper limit of the 90% CI exceeded 1.25. Detailed results for each pharmacokinetic parameter are presented in Table 2.
One patient in each treatment group reported an AE of mild intensity in the single-dose bioequivalence study MT-1186-J03; these AEs were not judged to be reasonably related to the investigational products by the investigator. No serious AEs (SAEs), no withdrawals due to AEs, and no AEs of special interest were reported in the study.
Results from the single-group safety study MT-1186-A01 in patients with ALS were reported for the 24-week interim analysis. Seventy-nine percent of patients experienced at least 1 AE; however, discontinuation due to AEs was low (6%), suggesting the harm profile might be considered acceptable. SAEs were reported by 11% of patients; the most frequently reported were likely related to the disease: ALS (n = 5), dyspnea (n = 3), and respiratory failure (n = 3). Six patients died over the 24-week study period; causes of death were respiratory failure (n = 3), pneumonia (n = 1), suicide (n = 1), and ALS (n = 1). Among AEs of special interest, 8 patients reported cardiac disorders. All cardiac events arose from electrocardiogram findings, with the exception of 1 patient with cardiac failure, so the sponsor considered that they did not reveal a signal of concern. Key harms results are presented in Table 3.
The most significant limitation associated with the included trials is the study designs. The bioequivalence design in healthy participants and the open-label uncontrolled study are not sufficient to evaluate the comparative clinical value added for the drug in the target population for reimbursement. The key assumption of the submission is that as IV edaravone has been approved by Health Canada and recommended for reimbursement by CADTH, establishing bioequivalence is sufficient to establish the clinical value of oral edaravone. However, the 2 formulations (solution for injection and oral suspension) cannot be considered bioequivalent since they involve 2 different dosing forms. Whether they can be considered to display comparable bioavailability of edaravone upon administration is to be assessed by Health Canada during formal review. While there is merit and supporting precedent to the assumption of comparable bioavailability, there remains a degree of uncertainty as to the true treatment effects of oral edaravone given the bioequivalence study design (i.e., single administration, assessing pharmacokinetic parameters with estimates falling within a range of acceptable values to establish equivalence) and the lack of comparative evidence between the oral and IV formulations’ effects on clinical outcomes.
The single-dose bioequivalence study MT-1186-J03 does not inform on the efficacy of a Health Canada–approved dosing regimen of oral edaravone in patients with ALS in terms of outcomes relevant to patients living with the disease. That study MT-1186-A01 was an open-label, uncontrolled trial subjects the study to a high risk of bias and limits the conclusions that can be drawn from the findings. The lack of comparative data for the outcomes of motor function, mobility, muscle pain, and fatigue, as well as difficulty breathing and speaking, which were identified by patients with ALS as the most important symptoms to control according to the patient input received, is an important gap in the evidence.
At the submitted price of $9,200 per 1,050 mg of edaravone per 50 mL of suspension or $12,880 per package of two 735 mg (35 mL) bottles, the annual drug cost per patient of treatment with oral edaravone is $123,280 in the first year and $119,600 per subsequent year, which is equivalent to the drug acquisition cost of IV edaravone at publicly available prices. CADTH conducted a reanalysis of the sponsor-submitted cost comparison, considering that costs associated with IV administration and IV-related AEs differ in the first and subsequent years of therapy. In this analysis, where some of the IV administration costs were assumed to be borne by the sponsor’s patient support program (PSP), oral edaravone was associated with an average cost saving to the public health care payer of $1,649 per patient compared to IV edaravone in the first year of therapy, and $1,105 per patient in subsequent years of therapy.
The cost comparison assumes clinical similarity between the oral and IV formulations of edaravone, based on the sponsor’s submitted single-dose bioequivalence study and an uncontrolled, open-label safety study. CADTH was unable to account for uncertainties in the comparative clinical effectiveness and safety between edaravone products or for the confidential pricing and stipulations that may have been negotiated for IV edaravone.
Findings from the sponsor’s analysis of bioequivalence suggested that oral edaravone showed comparable bioavailability to its IV formulation in a population of healthy volunteers; however, this requires formal assessment by Health Canada. Since IV edaravone was found to slow the rate of decline in motor function in patients with ALS, comparable bioavailability would suggest that the same conclusion may apply to oral edaravone. Findings from a single-group safety study suggest that the harms profile of oral edaravone may be considered acceptable, and no major safety signal was identified. However, the level of confidence in the evidence is highly affected by several limitations, including the open-label, uncontrolled trial design of the study, which introduced a high risk of bias. The lack of comparative data with oral edaravone for the outcomes of motor function, mobility, muscle pain, and fatigue, as well as difficulty breathing and speaking, which were identified by patients with ALS as the most important symptoms to control according to the patient input received, remains a gap in the evidence. Input received from all sources, including patients with ALS, clinicians, and the clinical expert consulted by CADTH for this review, emphasized that an oral version of edaravone would be a lot easier for patients to access than its IV formulation, reducing the risk of exposure to unnecessary infusion-associated AEs and decreasing the burden related to the IV administration, both to the health care system and to patients with ALS themselves.
At the submitted price, the annual drug cost of oral edaravone is $123,280 per patient in the first year and $119,600 per patient in subsequent years, which is the same as the annual drug cost of IV edaravone. When costs associated with IV administration and IV-related AEs are considered, and taking into account the sponsor’s PSP, which funds some IV administration costs, oral edaravone is $1,649 less expensive per patient than IV edaravone in the first year and $1,105 less expensive in subsequent years. The results are based on publicly available list prices for IV edaravone and may not reflect actual prices paid by Canadian public drug plans.
ALS is a progressive neuromuscular disorder characterized by the degeneration of UMNs and LMNs.1 Symptoms of ALS are typically first noticed when limb weakness occurs, though the first symptoms can also be bulbar and involve difficulty in speaking or swallowing. Over time, patients lose function in additional regions, such as other limbs and respiratory muscles. Progressive muscle weakness occurs, and eventual respiratory failure leads to death. Patients present with symptoms in adulthood,2 and the median survival time from onset to death estimated from population-based studies ranges from 20 months to 36 months.3 ALS is a clinically heterogeneous disease in terms of presentation and rate of progression. For example, 5% to 10% of patients with ALS survive past 10 years from onset.3 Approximately 10% of ALS cases are familial ALS. The etiology of the disease is unknown, and at least 25 genes have been reproducibly shown to be associated with ALS.2
There is no definitive test for diagnosing ALS, and there can be a long duration from symptom onset to diagnosis. The diagnosis is based on clinical examination, electrophysiology tests, and exclusion of mimics. The lack of a useful biomarker of ALS contributes to delays in the diagnosis of ALS and difficulty in monitoring disease progression or activity in response to treatment.11 Expert consensus on diagnostic criteria was established in 1994 with the El Escorial criteria, and a subsequent version was established in 1999 as the El Escorial revised Airlie House criteria.12 The criteria have been mainly used for standardizing clinical trials as opposed to diagnosing patients in clinical practice.12 In the revised criteria, patients are categorized as having clinically “definite ALS,” “probable ALS,” “probable ALS — laboratory supported,” or “possible ALS.” The criteria are based on the presence of UMN or LMN signs in 4 regions of involvement — the brainstem, and the cervical, thoracic, and lumbosacral spinal cord — and are as follows:13
A systematic review published in 20094 summarized the results from 5 studies reporting incidence of ALS in 3 Canadian provinces, with 3 studies in Nova Scotia, 1 in Ontario, and 1 in Newfoundland and Labrador. Estimates of age-adjusted annual incidence per 100,000 persons ranged from 2.0 to 2.3 in 4 studies, with the fifth study estimating a crude annual incidence rate of 2.4 per 100,000 persons in Newfoundland and Labrador. Since the 2009 systematic review, 1 study of incident cases from 2010 to 2015 in British Columbia estimated a crude annual incidence rate of 3.29 per 100,000 persons14 and 1 study in the region of Saguenay-Lac-Saint-Jean in Quebec found an annual crude incidence of 3.01 per 100,000 persons during the period of 2005 to 2009.15
There is no cure for ALS. Health Canada–approved treatments for ALS include riluzole and edaravone. Riluzole is an oral medication that has been shown to extend tracheostomy-free survival by 2 months to 3 months in patients with ALS.7 Riluzole is contraindicated for patients with hepatic disease or elevated liver enzymes, and AEs reported by patient respondents include cramps, diarrhea, heartburn, and feeling sick. Edaravone, a free radical scavenger thought to prevent oxidative damage to vascular endothelial cells and nerve cells, is currently available as an intravenously administered drug that has been found to slow the rate of decline in motor function.6 According to clinical expert opinion, it is typically administered concomitantly with riluzole but had a low uptake at the time of this review resulting from provincial drug coverage and patient choice due to the practicalities of the administration.
ALS symptoms may be managed (to varying degrees) by a range of pharmacologic therapies, including antidepressants, antianxiety and sleeping medications, medications to manage sialorrhea, and medications to address constipation.
Multidisciplinary nonpharmacologic care is important for managing symptoms and improving quality of life for patients with ALS. Multidisciplinary care optimally should involve a neurologist, a gastroenterologist, a respiratory physician, and a palliative care physician, as well as health care practitioners in the following areas: specialist nursing, physiotherapy, occupational therapy, nutrition, speech language pathology, and psychology.16-18 In Canadian clinics, the decision to introduce noninvasive ventilation is mostly based on patient symptoms (dyspnea, orthopnea, and morning headache), nocturnal oximetry, and FVC, and a survey published in 2010 found that 18.3% of patients with ALS living in Canada were using noninvasive ventilation.19 Patient intolerance and lack of access to a respirologist or ventilation technologist were identified as the most common barriers to utilization.19 As a second-line respiratory intervention, the use of invasive ventilation with a tracheostomy is associated with high cost and emotional and social impacts. The insertion of a gastrostomy feeding tube is recommended in Canadian,1 US,18 and European16 guidelines to supplement nutrition and stabilize weight loss. Decline in respiratory function, dysphagia, and weight loss factor in to the decision to place a feeding tube, though decision-making criteria vary between Canadian clinics.20
This reimbursement review report evaluates orally administered edaravone, which is available as an oral suspension of 105 mg of edaravone per 5 mL of suspension. The Health Canada–approved indication is for the treatment of patients with ALS. According to the draft product monograph, the Health Canada–recommended dose of oral edaravone is 105 mg (5 mL) taken orally or via a feeding tube (percutaneous endoscopic gastrostomy or nasogastric tube). The recommended treatment regimen starts with an initial treatment cycle of daily dosing for 14 days followed by a 14-day drug-free period. Subsequent treatment cycles involve daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods. Edaravone oral suspension should be taken in the morning after fasting overnight for at least 8 hours and waiting at least 1 hour before eating or drinking anything except water.7 For patients who are unable to fast overnight, the required fasting interval can be shortened depending on the type of meal. Patients treated with 60 mg of edaravone injection may be switched to 105 mg (5 mL) edaravone oral suspension using the same dosing frequency. Upon switching to edaravone oral suspension, patients should follow edaravone oral suspension dosing recommendations with regard to food consumption.7
Edaravone injection was recommended for reimbursement for the treatment of ALS by CDEC in March 2019,6 if CDEC-specified conditions were met:
This section was prepared by CADTH staff based on the input provided by patient groups.
One patient advocacy group, the ALS Society of Canada, submitted the patient input for this review. The ALS Society of Canada is a registered charity working nationally to respond to the urgent unmet need for life-changing treatments through investments in research and engagement of various stakeholders to advocate for equitable, affordable, and timely access to proven therapies. The submission was based on an online survey disseminated in English and French in November 2021 and on telephone interviews with 7 patients who had experience with oral edaravone in February and March 2022. A total of 629 patients and caregivers responded to the online survey, primarily from Ontario and Quebec. Approximately 70% of respondents are, or were, caregivers to someone diagnosed with ALS, the remainder being patients living with the disease.
Respondents indicated that the most severe of ALS symptoms include difficulties with mobility (including walking and standing), gripping or holding things, muscle cramping or twitching, and fatigue caused by muscle exhaustion. These symptoms were also among the most important to control for people living with ALS, in addition to difficulties breathing, speaking, and swallowing. Patients indicated that their social life, travel and hobbies, and family life suffered the most. In addition, caregivers of patients with ALS highlighted a negative impact on emotional and psychological well-being, including pervasive feelings of overwhelming grief and struggles with mental health, including stress, anxiety, helplessness, and hopelessness. Loss of independence was mentioned as touching all aspects of patients’ lives and dramatically impacting caregivers, as patients eventually need help performing all daily tasks. Patients and caregivers reported treatment experience with riluzole and IV edaravone. Slowing disease progression, maintaining ability to participate in daily activities, and increasing survival were identified as the most important benefits from therapy. Access to riluzole and IV edaravone treatments was a problem for some patients. Other difficulties reported with edaravone were mostly related to the IV administration, including patients having to schedule activities of daily living around their infusion schedule and needing to have a port catheter implanted.
A copy of the patient input from the ALS Society of Canada is available with this report.
All CADTH review teams include at least 1 clinical specialist with expertise in the diagnosis and management of the condition for which the drug is indicated. Clinical experts are a critical part of the review team and are involved in all phases of the review process (e.g., providing guidance on the development of the review protocol; assisting in the critical appraisal of clinical evidence; interpreting the clinical relevance of the results; and providing guidance on the potential place in therapy). The following input was provided by 1 clinical specialist with expertise in the diagnosis and management of ALS.
The clinical expert consulted by CADTH indicated that there is currently no treatment available to reverse the disease or to stop the progression of neurologic decline. Therefore, the mainstay of care for patients diagnosed with ALS consists of interventions and supports to manage symptoms. The 2 approved treatment options at the time of this review were riluzole and IV edaravone, both only showing modest benefits in slowing disease progression.
The clinical experts believed that an ideal treatment would delay or prevent disease progression (i.e., motor neuron degeneration), slow decline in lung capacity, reduce severity of symptoms, minimize AEs, reduce loss of cognition, improve health-related quality of life, and ultimately increase patients’ ability to continue to work, reduce burden on caregivers, and prolong life. Otherwise, the goals of treatment should include symptom management and quality-of-life optimization, which are priorities in patient care. An ideal treatment would also comprise a delivery mechanism that is safe, convenient, and pragmatic for patients and caregivers based on patient preference, stage of disease, and pathology.
At the time of this review, the only Health Canada–approved disease-modifying treatments for ALS were riluzole and IV edaravone, while AMX0035 is approved for use under the Special Access Program and is also under CADTH review. Riluzole, which acts by suppressing excessive motor neuron firing through inhibition of glutamate, prolongs survival by a median duration of 3 months. IV edaravone, which reduces oxidative stress, has been shown to slow the rate of clinical decline by 33% compared to IV placebo in a select group of patients with preserved respiratory function and disease duration of less than 2 years.
As the cause of ALS remains unknown, multiple pathogenic mechanisms are thought to be involved in the neuronal death process that starts even before the manifestation of clinical symptoms. Therefore, the clinical expert emphasized the importance of targeting all potential pathological pathways early. The expert indicated that patients would usually be prescribed riluzole for its clinical benefits and because it is easily administered and well tolerated. Patients meeting the criteria for reimbursement would then be offered IV edaravone. According to the clinical expert, the uptake of the medication has so far been low, in part because the IV formulation is invasive and comes with a time-consuming administration schedule. The coexistence of IV and oral edaravone formulations would provide options for drug administration based on patient preference, safety, and convenience, as well as progression and evolving pathology; however, the opinion of the clinical expert consulted by CADTH is that the more convenient and safer oral formulation of edaravone would be likely to replace the IV formulation.
The clinical expert indicated that patients must first be diagnosed with ALS by a specialist. Since no specific diagnostic biomarker exists, the diagnosis is made based on a patient’s history, physical examination, electrodiagnostic examination, and exclusion of alternative diagnoses. Suitability for treatment is therefore made clinically. The clinical expert anticipated that all patients with ALS could benefit from oral edaravone. However, the patients with the greatest need for a new treatment are those patients with a maintained physical motor function that could be preserved with the administration of edaravone. Patients whose disease is at a stage where the clinician believes there is no expected benefit from progression mitigation, who completely rely on the help of a caretaker, may be less suitable for treatment with oral edaravone. As with all treatment decisions, this would be made in consultation with the patient, informed by the clinical judgment of the treating physician.
The clinical expert mentioned that for patients with ALS, disease progression will continue despite best therapeutic efforts. Furthermore, the rate of disease progression varies between individuals, and as yet, there are no biomarkers to discern treatment response within a single patient. A specific treatment’s benefit in an individual is only apparent when compared against the average trajectory of natural disease history.
As such, the clinical expert indicated that current standard of care involves following the patient at regular intervals and monitoring their physical, functional, emotional, and quality-of-life parameters. Medications will be titrated appropriate to a patient’s condition and their goals of care, in a palliative-focused approach.
According to the clinical expert, patients will have regular visits with their ALS care team to review their clinical status and goals of treatment. It is reasonable to expect that goals of treatment will change as the disease progresses. Therefore, medication could be continued until the philosophy of care shifts to a palliative focus and/or the clinician feels there is no expected benefit from progression mitigation.
The clinical expert highlighted the importance for patients to be appropriately diagnosed and followed by a multidisciplinary ALS clinic that delivers team-based care, including neurology, physiatry, respirology, and allied health professionals. The multidisciplinary care team will also address issues including communication, nutrition, swallowing, mobility, activities of daily living, respiratory care, cognition, psychosocial issues, medical management, and end-of-life care. Patients receiving edaravone should, at minimum, be followed by a neurologist or physiatrist experienced in the care of patients with ALS.
Based on the clinical expert’s experience, it would not be appropriate to recommend that patients try other treatments before initiating oral edaravone. There are no biomarkers to discern how well an individual patient would respond to a specific treatment. Though good clinical practice would allow time to confirm a patient’s tolerance on 1 medication, requiring the patient to demonstrate “failure” before introduction of another treatment would subject them to irreversible progression that would otherwise have been slowed had other therapies been given concurrently and would not be reflective of current evidence and practice.
The clinical expert consulted by CADTH indicated that the oral formulation of edaravone would provide clinicians and patients with a safe and pragmatic option for drug administration, given that it is expected to require less equipment (e.g., IV or central venous access) and personnel (e.g., medical staff to insert and maintain this equipment at the clinic or in the patient’s home) to administer. The clinical expert considered that the oral formulation would be a well-received alternative, as many patients choose not to embark on the currently available IV formulation because of the caveats and excessive requirements and constraints related to IV infusion.
This section was prepared by CADTH staff based on the input provided by clinician groups.
One clinician group provided input. CALS is a national network of clinicians working in academic health care centres across Canada and specializing in ALS research and clinical care. The network established in 2008 aims to connect Canadian ALS clinical research centres and to improve both patient and clinic participation in clinical research. All members of CALS were invited to participate in a virtual meeting in March 2022 to discuss key questions related to oral edaravone. Eleven CALS members from across Canada attended the meeting.
Overall, the clinician group input submission was consistent with the expertise provided by the clinical expert that was part of the CADTH review team.
A copy of the clinician group input is available with this report.
The drug programs provide input on each drug being reviewed through CADTH’s reimbursement review processes by identifying issues that may impact their ability to implement a recommendation. The implementation questions and corresponding responses from the clinical expert consulted by CADTH are summarized in Table 5.
Note that the clinical evidence summarized in this section was prepared by the sponsor in accordance with the CADTH tailored review process and has not been modified by CADTH.
Study MT-1186-J03 was designed as a 2-group, 2-period crossover study with the objective of investigating the bioequivalence between edaravone oral suspension and edaravone IV formulation in healthy subjects by assessing each pharmacokinetic (PK) parameter with the bioequivalence limit. The study was planned in accordance with the “Guideline for Bioequivalence Studies of Generic Products and the Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerations.” A crossover design was selected for this study in order for PK parameters to be precisely compared in a small number of subjects.
The study took place at a single site in Japan, and 42 healthy Japanese adults were included. A randomization key code table was created and provided it for the investigator, and subjects were randomly allocated to one of two groups: advance administration of edaravone oral suspension group (PO - IV) and the advance administration of edaravone IV formulation group (IV - PO).
Subjects who met all of the following criteria and were capable of giving informed consent were included in the study:
Age-restricted healthy adult volunteers were selected as the study population in order for the subject backgrounds to be uniform as much as possible and for this study to conform with the “Guideline for Bioequivalence Studies of Generic Products”d and the Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs - General Considerationse, which specify that the subjects should be healthy adult volunteers in principle. In addition, the subjects were limited to Japanese in order for PK to be evaluated in Japanese.
Subjects who met any of the following criteria between screening and investigational product administration were excluded from the study:
The rationales for setting were to: ensure the safety of subjects and to exclude unhealthy subjects (exclusion criteria #1); to perform the study safely and ethically (#2, 3, 5, 6, 19); to reduce PK variability due to BMI differences (#4); to ensure the safety of subjects, volumes and intervals of blood sampling were set with reference to the “Enforcement Regulations for the Act on Securing a Stable Supply of Safe Blood Products” (#7, 8); to avoid a possible effect on PK (#9, 13, 15, 16, 17); To assure subject safety, even though there were no toxicity findings at the highest dose of 200 mg/kg in the reproductive and developmental toxicity studies (#10, 18); to avoid possible effects on assessment results of this study (#11, 14); and To perform the study ethically and to avoid any unpredictable effects of drugs whose efficacy and safety have not been established (#12).
No meaningful differences were found between the advance administration of edaravone oral suspension group (PO - IV) and the advance administration of edaravone IV formulation group (IV - PO) groups. There were no subjects who had medical history and complications at the start of the study.
A commercially available product of edaravone (RADICUT BAG for IV infusion 30 mg; Mitsubishi Tanabe Pharma Corporation, Osaka, Japan) was used for the IV formulation. A 105-mg dose of edaravone oral suspension was selected for assessment so it would provide PK parameters (AUCs) corresponding to those of the approved 60-minute IV infusion of edaravone 60 mg, as predicted in previous studiesf.
In order for bioequivalence between edaravone oral suspension and edaravone IV formulation to be examined, these drugs were to be administered in the fasting state for at least 10 hours and the fasting was to be continued until 4 hours after the administration.
After fasting for at least 10 hours, the subjects drank 100 mL of water 1 hour before investigational product administration. After receiving administration of the investigational product, edaravone oral suspension 105 mg (105 mg/5 mL), the subjects drank 100 mL of water. They fasted until the completion of blood sampling performed 4 hours after the administration. Drinking water other than the water provided at the time of administration was prohibited from 1 hour before to 1 hour after investigational product administration.
After fasting for at least 10 hours, the subjects received continuous IV infusion of edaravone IV formulation 60 mg (30 mg/100 mL formulation, 2 bags) over 1 hour. The subjects fasted until the completion of blood sampling performed 4 hours after the administration. Drinking water was prohibited from 1 hour before the investigational product administration to 1 hour after the completion of the administration.
After fasting for at least 10 hours, the subjects received continuous IV infusion of edaravone IV formulation 60 mg (30 mg/100 mL formulation, 2 bags) over 1 hour. The subjects fasted until the completion of blood sampling performed 4 hours after the administration. Drinking water was prohibited from 1 hour before the investigational product administration to 1 hour after the completion of the administration.
After fasting for at least 10 hours, the subjects drank 100 mL of water 1 hour before investigational product administration. After receiving administration of the investigational product, edaravone oral suspension 105 mg (105 mg/5 mL), the subjects drank 100 mL of water. They fasted until the completion of blood sampling performed 4 hours after the administration. Drinking water other than the water provided at the time of administration was prohibited from 1 hour before to 1 hour after investigational product administration.
Subjects were to be withdrawn from the study if any of the following scenarios occurred:
If a subject discontinued participation in the study between the end of investigational product administration in period I and the completion of safety assessment, the investigator (or sub investigator) was to take appropriate actions for the subject, and promptly report to the monitor regarding the subject’s withdrawal from the study. Within 3 days from the last dose, the investigator (or sub investigator) was to perform the tests and observations that were specified for the withdrawal assessment.
The investigator (or sub investigator) was to record the date, the reason for discontinuation along with detailed information, the course of events that had led to the discontinuation, and treatment that had been provided in the case report form (CRF). If the onset of an AE was the cause of the discontinuation of the subject, the investigator (or sub investigator) recorded the AE in the discontinuation section in the CRF. The date of discontinuation was the date when evaluation had been performed (the date of evaluation) at the time of discontinuation. However, when evaluation was impossible, the date of discontinuation was to be the date when it had been judged that the subject was withdrawn from the study.
If the subject missed the observations and tests that were to be performed within 3 days from the last dose, or if he/she did not return to visits after discontinuation, the investigator (or sub investigator) was to make attempts to follow him/her up in order to identify the reason and subsequent course, by letter or phone, and record the results in the discontinuation section in the CRF.
Plasma and urine concentrations of unchanged edaravone and its metabolites were assessed with validated methodologies. PK parameters evaluated for unchanged edaravone after both IV and oral administration were AUC from time 0 to the last quantifiable concentration time point (AUC0-t), AUC0-∞, Cmax, time to reach Cmax (tmax), terminal elimination half-life (t1/2), bioavailability, total clearance (CL) or apparent CL after oral administration, urinary excretion ratio of drug from time 0 to 48 hours, and renal clearance. Volume of distribution at steady state and volume of distribution during the terminal phase were evaluated for IV edaravone. For sulfate and glucuronide conjugates, assessments included AUC0-t, AUC0-∞, Cmax, tmax, and t1/2. PK analysis was conducted for all subjects who received ≥1 dose of edaravone oral suspension or edaravone IV and who had evaluable PK data.
Safety assessments included AEs, serious AEs (SAEs), adverse drug reactions (ADRs), and serious ADRs. The safety analysis set consisted of all subjects who received ≥1 dose of edaravone oral suspension or edaravone IV.
Descriptive statistics (number of subjects, mean value, standard deviation, minimum value, median value, and maximum value) were used to calculate for the numerical data, and frequency and percentage will be calculated for each category for the categorical and ordinal data. Demographic characteristics and other baseline characteristics, frequency and percentage were calculated for the discrete values, and descriptive statistics were calculated for the numerical data. The calculation was made for each group.
For assessment with the bioequivalence limit, the analysis of variance was conducted for the log-transformed AUC0-t, AUC0-∞, and Cmax of unchanged edaravone, which included factors accounting for the following sources of variation: sequence, subjects nested in sequences, period, and treatment. Estimates of the mean difference between formulations (oral suspension minus IV formulation) on the log scale and 90%CI for the difference were back transformed to present mean ratios and their 90%CIs for oral suspension to IV formulation. The estimated 90%CIs of the geometric mean ratios were examined to lay entirely within the standard bioequivalence limits of 0.80 and 1.25. For reference, the same analysis was also performed on other PK parameters of unchanged edaravone, such as tmax, AUC from time 0 up to the last sampling time point for all time points, and elimination rate constant from the central compartment (Kel). Values of tmax were not log-transformed prior to statistical analysis.
For the safety assessments, AEs were summarized by treatment and into multiple categories. Laboratory tests, vital signs,12-lead ECGs and physical examination data were summarized and presented.
The necessary total number of subjects was based on the AUC0-∞ and Cmax data for unchanged drug obtained in previous studies f,h. The calculation was performed so that for AUC0-∞, the 2-sided 90% confidence interval (CI) of the mean ratio of edaravone oral suspension to edaravone IV would fall within the bioequivalence criterion of 0.80 to 1.25; and for Cmax, the lower limit of the 2-sided 90%CI would exceed 0.80. The intraindividual standard deviations of log-transformed AUC0-∞and Cmax were assumed to be 0.232 and 0.706, respectively, from the previous study. Assuming that the expected ratios of AUC0-∞ and Cmax of edaravone oral suspension to edaravone IV were 1.06 and 1.40 from the 4-parameter logistic model, the necessary total numbers of subjects calculated on the basis of 2 one-sided tests with a significance level of 5% and power ≥90% were 36 and 24, respectively. Accordingly, sample size was set at 42 with 21 subjects per group to allow 36 subjects to complete the 2 periods.
Parameters required for PK evaluation were selected with reference to the Guideline for Bioequivalence Studies of Generic Productsd and the Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs – General Considerationse, and Clinical Pharmacokinetic Studies of Pharmaceuticals i.
It should be stated if the analysis was based upon the intention-to-treat (ITT) or per-protocol (PP) population. All formal statistical tests of treatment effects were done at a two-sided significance level of 0.05. Point estimates were accompanied with two-sided 95% CIs where applicable.
Drug Concentrations and Confirmatory PK Assessments
The PK analysis set consisted of all subjects who received at least 1 dose of the investigational product and had evaluable PK data. The PK parameters were calculated using WinNonlin® software (version 6.3). Summaries of concentrations and PK parameters, and statistical analysis for unchanged edaravone, sulfate conjugate, and glucuronide conjugate were performed using data from subjects whose PK data were available in both formulations. For each formulation, individual plasma concentrations vs. actual time for unchanged edaravone, sulfate conjugate, and glucuronide conjugate were plotted on both linear/linear and log/linear scales. Mean plasma concentrations vs. nominal time curves were plotted on both linear/linear (+SD) and log/linear scales overlaid by both formulations.
The parameters AUC0-t, AUC0-∞ and Cmax of unchanged edaravone were log transformed prior to statistical analysis. The analysis was performed by analysis of variance (ANOVA), which included factors accounting for the following sources of variation: sequence, subjects nested in sequences, period, and treatment. Estimates of mean difference between formulations (oral suspension minus IV formulation) on the log scale and 90% CI for the difference (based on the residual mean square in the ANOVA) were back transformed to present means and 90%CI for the ratio of oral suspension to IV formulation.
90%CI for the ratio of AUC0-t, AUC0-∞ and Cmax of unchanged edaravone which lied entirely within the limits of 0.8000 to 1.2500 provides bioequivalence between IV formulation and oral suspension
For non-PK related AEs, if severity or relationship was found to be missing, the most severe occurrence would be imputed for the summary of interest. For safety summaries, only observed data was used and unless otherwise specified, missing safety data would not be imputed. For PK summaries, only observed data was used. Missing plasma concentration data would not be imputed. When calculating Ae and Ae%, missing urine concentration data would be imputed to 0.
N/A
N/A
As reference, the same analysis as described in the primary outcomes section was also conducted on AUC0-t, AUC0-∞ and Cmax of sulfate conjugate and glucuronide conjugate and the other reference PK parameters of unchanged edaravone, sulfate conjugate, and glucuronide conjugate, such as tmax, AUC0-all, MRT0-∞, and Kel. Tmax was not log transformed prior to statistical analysis.
All AEs were coded according to MedDRA (version 22.0). Overall summary for the following category was conducted by treatment.
The following summaries were also conducted by treatment. These tables were ordered by International Agreed Order for System Organ Class (SOC) and then by alphabetical order for Preferred Term (PT).
Each of the summaries was done at the subject level - multiple occurrences of the same event within a subject was counted once in the summaries by SOC and PT; multiple occurrences of the same event within a subject was counted once in the maximum severity category (severe > moderate > mild) and/or maximum drug relationship category (reasonable possibility/no reasonable possibility) and/or the earliest duration. All AEs were listed.
For laboratory tests, absolute values and changes from baseline, except for urinalysis were summarized descriptively by group and scheduled visit. For urinalysis, number and percentage were presented. Shift tables presented the changes in clinically relevant categories from baseline to each scheduled post-baseline visit by group. All data including clinically relevant flagged were listed. Any data below the limit of quantification were treated as 0 in summary statistics.
Absolute values and changes from baseline for vital signs were summarized for the parameters (systolic blood pressure, diastolic blood pressure, pulse rate, body temperature) by treatment and scheduled time-point. All data were listed.
For 12-lead ECGs, Absolute values and changes from baseline were summarized for the parameters (heart rate, PR, RR, QRS, QT, QTcF) by treatment and scheduled time-point. The percentage of subjects with 12-lead ECG values outside pre-defined limit was summarized by treatment and scheduled time-point. All data (including overall evaluation) were listed.
For physical examinations, all data were listed.
All safety assessments were conducted on the safety analysis set (SAF) population. The consisted of all subjects who received at least 1 dose of the investigational product.
The study included 42 subjects (n = 21 in each group). The baseline demographic characteristics of the study population are summarized in Table 7. |||||||| subjects gave informed consent and were screened, however |||||| failed screening due to withdrawal of consent, were excluded based on the exclusion criteria, or withdrew for other reasons. While the eligible population included |||||| subjects, ||||| were kept as reserve subjects, with 42 subjects randomized to each of the advance administration of edaravone oral suspension group (PO - IV) and the advance administration of edaravone IV formulation group (IV - PO). Table 8 summarizes the disposition of subjects in the study.
The PK analysis set consisted of all subjects who received at least 1 dose of the investigational product and had evaluable PK data. The SAF also consisted of all subjects who received at least 1 dose of the investigational product. Investigational products were administered to a total of 42 subjects (21 subjects for each group) by both of a single IV infusion over 60 minutes and a single oral administration in fasted conditions. No subjects discontinued this study after the start of administration of the investigational product.
One subject in the IV - PO group took magnesium oxide as medication due to AE (constipation) at 5 hours and 29 minutes after oral administration. However, taking into account the time of the administration of the concomitant drug, magnesium oxide was judged not to affect the PK of edaravone. No other concomitant medication use was noted in either treatment group.
In 42 healthy Japanese subjects, this study demonstrated that the 105 mg oral suspension of edaravone has equivalent AUC0-t and AUC0-∞ of unchanged edaravone to the approved 60 mg IV formulation [Geometric mean ratio (90% CI): 0.974 (0.914-1.038) for AUC0-t and 0.977 (0.917-1.041) for AUC0-∞]. Geometric mean ratio of Cmax of the oral suspension compared to the IV formulation and its lower limit of 90% CI were also within the range of 0.80 to 1.25, while the upper limit of 90% CI exceeded 1.25 as anticipated [Geometric mean ratio (90% CI): 1.217 (1.090-1.359)].
The results for the plasma concentration of unchanged edaravone for the oral suspension and IV formulation are summarized in Table 9 and Figure 2. Both oral and IV administration of edaravone showed a 3-phase elimination after reaching Cmax, and the plasma concentration-time profiles of unchanged edaravone were very similar regardless of the administration route. The median tmax values of unchanged edaravone in 105 mg oral suspension and 60 mg/60 min IV formulation were 0.50 and 1.00 hour, respectively. The mean AUC0-t, AUC0-∞ and t1/2 of unchanged edaravone were similar between two formulations. The mean absolute bioavailability (F) of the oral suspension was 57.3%.
Figure 3 presents the plasma PK parameters and concentration-time profiles for the edaravone sulfate and glucuronide conjugates following administration of the 105 mg edaravone oral suspension and 60 mg edaravone IV. The mean plasma concentrations of both sulfate and glucuronide conjugates with the 105 mg oral suspension were higher than those with the 60 mg IV formulation, but the shape of the profiles and elimination patterns were similar between the two formulations after reaching Cmax.
Edaravone was eliminated into urine mainly as glucuronide conjugate and to a lesser extent as sulfate conjugate after administration of both the oral suspension and the IV formulation. The mean Ae% of sulfate conjugate for 48 hours after administration were 6.58% and 8.09% in 105 mg oral suspension and 60 mg/60 min IV formulation, respectively. The mean Ae% of glucuronide conjugate for 48 hours after administration were 59.8% and 78.4% in 105 mg oral suspension and 60 mg/60 min IV formulation, respectively. The mean Ae% of sum of unchanged edaravone, sulfate and glucuronide conjugates for 48 hours after administration were 67.0% and 87.3% in 105 mg oral suspension and 60 mg/60 min IV formulation, respectively. The urinary excretion of unchanged edaravone was low, and the composition ratios of unchanged edaravone and the metabolites in urine were similar for both administration routes. Urine PK parameters are presented in Table 10.
The safety analysis set (SAF) consisted of all subjects who received at least 1 dose of the investigational products. Investigational products were administered to a total of 42 subjects (21 subjects for each group). No subjects discontinued this study after the start of administration of the investigational product.
A total of 2 AEs were reported in 2 subjects, one AE for each formulation (IV formulation: aspartate aminotransferase increased, oral suspension: constipation). All AEs were mild in severity and recovered. None of AEs were judged to be reasonably related to the investigational product by the investigator. No ADRs, SAEs, serious ADRs and AEs leading to discontinuation and/or to death occurred. A summary of AEs is presented in Table 11.
Hematology, biochemistry, coagulation, and urinalysis over time for patients were collected. No clear trends over time were observed for most safety laboratory parameters in any group during this study.
Absolute values and changes from baseline in vital sign parameters for patients were collected. Overall, all vital signs were stable, and there were no notable trends in any formulation during this study.
Absolute values and changes from baseline and overall evaluations in 12-lead ECG parameters were recorded for patients. No notable trends were observed in 12-lead ECG parameters in any formulation during this study.
Normal and abnormal status of physical examination by patient was recorded. No notable trends were observed in physical examination in any formulation during this study.
Overall, the two formulations for edaravone of 105 mg oral suspension and 60 mg IV formulation were well tolerated and there were no safety concerns in the results of this study.
A total of 2 AEs were reported in 2 subjects, one AE for each formulation. Both AEs were mild in severity and recovered during the study. There were no AEs that were judged to be reasonably related to the investigational products by the investigator. One subject in the PO - IV group experienced aspartate aminotransferase increased on day 11, i.e., during the follow-up period after IV administration and her aspartate aminotransferase returned to normal range at the unscheduled visit on day 24 without treatment. Another subject in the IV - PO group experienced constipation after oral administration of the investigational product on day 4. The subject took the concomitant medication (magnesium oxide) for the AE on days 4 and 5 and recovered on day 6.
There were no serious adverse events (SAEs) reported in this study.
There were no withdrawals due to AEs in this study.
There were no AEs of special interest in this study.
The results of the statistical analysis of the AUC0-t and AUC0-∞ of the IV formulation of edaravone 60 mg compared with the oral suspension of edaravone 105 mg were determined to be equivalent (geometric mean ratio [90%CI], 0.97 [0.91-1.04] and 0.98 [0.92-1.04], respectively). The geometric mean ratio of Cmax of the 105-mg oral suspension compared to the 60-mg IV formulation was within prespecified limits, but the upper limit of 90%CI exceeded 1.25 (geometric mean ratio [90% CI], 1.22 [1.09-1.36]). The least squares mean difference and 90%CI for tmax (the 105-mg oral suspension minus the 60-mg IV formulation) was −0.56 (90%CI, −0.60 to −0.51). For the reference parameters, the geometric LS mean ratios and 90% CIs of unchanged edaravone between the 2 formulations were 0.976 (90% CI: 0.917-1.039) for AUC0-all, 1.064 (90% CI: 0.970-1.167) for MRT0-∞, 0.935 (90% CI: 0.758-1.153) for Kel, and LS mean ratio and 90% CI for tmax were −0.559 (90% CI: −0.604- −0.513).
The statistical analysis with bioequivalence limits for the confirmatory plasma PK parameters (Cmax, AUC0-t, and AUC0-∞ of unchanged edaravone, and the geometric mean ratios and 90%CIs of unchanged edaravone between the 2 formulations) and the bioequivalence of the reference plasma PK parameters are summarized in Table 12.
Study MT-1186-A01 was designed as a phase 3, multi-center, open-label, safety study of oral edaravone administered over 48 weeks in subjects with ALS. The primary objective of the study was to evaluate the safety and tolerability of oral edaravone in subjects with ALS over 24 and 48 weeks, and an exploratory objective to evaluate the efficacy of oral edaravone in subjects with ALS over 24 and 48 weeks was also established. The clinical study report included in the CADTH submission currently describes the analysis at 24 weeks, with the 48-week data expected in the second quarter of 2022. The duration of the study for individual subjects will be approximately 51 weeks, consisting of a screening period of up to 3 weeks, an open-label treatment period of up to 48 weeks, and a safety follow-up period of 2 weeks after the last dose.
The dose selected for this study delivers a similar exposure as the IV edaravone infusion delivered at a dose of 60 mg over 60 minutes. To establish the long-term safety of oral edaravone in subjects with ALS, an identical dosing schedule to the approved IV formulation was utilized in this study.
A total of 185 subjects were enrolled. 23 subjects from four Canadian sites (two in Alberta and two in Quebec) were included in this study. Subjects meeting the eligibility criteria were enrolled into the 48-week open-label treatment period and received 105 mg of oral edaravone, following an overnight fast, and subjects continued to fast for at least 1 to 2 hours post-dose before the next meal (e.g., breakfast). An initial treatment cycle with daily dosing for 14 days was followed by a 14-day drug-free period. Subsequent treatment cycles included daily dosing for 10 days out of a 14-day period, followed by a 14-day drug-free period. Treatment cycles were 4 weeks in duration. The study design is outlined in Figure 4 below.
Exclusions Related to General Health or Concomitant Conditions:
Exclusions Related to Medications:
This study was conducted in 50 sites, located in Japan, the US, Canada, Germany, France, and Italy.
The enrolled population was mostly male (64%) and ranged in age from 22 to 75 years, with a median age of 61 years. Approximately 65% of the subjects were <65 years old, with 32% of subjects between 50 and 59 years old and 34% of subjects between 60 and 69 years old. Subjects who participated were located mostly in North America (51%) or Japan (35%). Demographic and baseline characteristics for the Enrolled Population are presented in Table 14.
Subjects received an oral dose of edaravone 105 mg suspension in the following regimen:
Treatment cycles were every 4 weeks. The dose of edaravone was taken after an overnight fast and subjects continued to fast for at least 1 to 2 hours post-dose before the next meal (e.g., breakfast).
This was an uncontrolled safety study. With the previous establishment of efficacy for IV edaravone in the treatment of ALS, placebo treatment was not considered appropriate. Concomitant use of riluzole was permitted throughout the study.
A subject was withdrawn from the study if the subject met any of the following criteria:
If a subject was withdrawn prematurely from the study, the date and the reason for withdrawal was recorded in the electronic Case Report Form (eCRF).
In the event that a subject dropped out of the study at any time, the reason for discontinuation was fully documented in the source documents and the eCRF. The Investigator site personnel documented the AEs and any other assessments in the source documents and made every effort to complete all required early termination (ET) assessments. Study sites followed up with subjects via phone calls at Weeks 24, 36, and 48 for event assessments. Subjects who withdrew from the study following enrollment were not allowed to re-enter the study.
The safety and tolerability of edaravone was evaluated and included the following safety assessments:
The functional and survival assessments of oral edaravone efficacy was also evaluated using the following:
The long-term safety and tolerability of oral edaravone was evaluated using descriptive statistics. For the exploratory efficacy analysis, point estimates and their associated 95% confidence intervals (CI) were presented. All data from all subjects enrolled into the study were included in subject data listings.
Continuous data were summarized descriptively using the number in the analysis population set (N), the number of observations (n), mean, standard deviation (SD), median, minimum, and maximum. Categorical data were summarized using frequency counts and percentages. The denominator for the percentages was the total number of subjects in the treatment group and analysis population being presented, unless otherwise specified. For visit-specific data, the number of subjects with non-missing observations at the visit in question were used as the denominator for percent calculations. Unknown, Not Done, Not Applicable and other classifications of missing data were not considered. Unscheduled or repeated assessments were not included in summary tables but were included in listings.
During the initial protocol development stage, a 30% dropout rate (based on the results of a previous Phase III study for the IV formulation of edaravone, Study MCI-186-19) was assumed over the course of the study, and thus approximately 150 subjects were planned to be enrolled to receive treatment with oral edaravone (105 mg) to obtain 1-year long-term safety data from approximately 100 subjects, However, while the study was ongoing and based upon the potential for a higher than expected premature termination rate due to the coronavirus disease (COVID-19) pandemic, the sample size was revised to enroll approximately 185 subjects to receive treatment with oral edaravone (105 mg) to obtain 1-year long-term safety data from approximately 100 subjects, meeting the requirement of ICH E1 guideline for long-term safety.
The long-term safety and tolerability of oral edaravone was evaluated using descriptive statistics.
Adverse Events: Adverse events were coded according to the MedDRA version 23.0. The frequency and incidence of TEAEs were summarized by SOC and PT. The SOC was sorted by International order; then within SOC, PT was sorted by PT code.
The following summaries were provided:
The numbers and proportions of subjects were calculated for the following:
Physical Examinations: Physical examination findings including reason not done were listed for the safety analysis population.
12-Lead Electrocardiogram: All ECG parameters were listed and analyzed for the safety analysis population. The ECGs were assessed by the investigator and deemed ‘Normal’, ‘Abnormal, not clinically significant’ (Abnormal, NCS), and ‘Abnormal, clinically significant’ (Abnormal, CS) and tabulated by visit up to Week 24 using frequency counts and percentages. In addition, the numerical ECG parameters and their change from baseline generated by the central ECG laboratory were summarized by descriptive statistics for each parameter by visit. A shift table describing the number and percentage of subjects shifting from non- potentially clinically significant values (PCSV) at baseline to PCSV at any time post- baseline values during treatment period was produced. The percentages were calculated from the number of subjects with available baseline values and any time post-baseline value.
Vital Signs Including Body Weight: Vital sign measurements (heart rate, supine and standing blood pressure [both systolic and diastolic], body temperature, and weight) and their change from baseline were listed and summarized for the safety analysis population using descriptive statistics by visit up to Week 24. Furthermore, supine minus standing blood pressure (both systolic and diastolic) and their change from baseline were summarized with descriptive statistics by visit. The body weight values and change from baseline to each post-baseline visit up to Week 24 were plotted by visit. A shift table describing the number and percentage of subjects shifting from non-PCSV at baseline to PCSV at any time post-baseline during treatment period was produced. The percentages were calculated from the number of subjects with a baseline value and any time post-baseline value. The number and percentage of subjects with orthostatic hypotension were tabulated by visit.
Laboratory Tests: All laboratory data were listed and analyzed for the safety analysis population. Laboratory data and change from baseline (hematology, biochemistry, or urinalysis) were summarized with descriptive statistics (continuous variables) or as distributions (categorical variables) by visit up to Week 24 except for pregnancy test parameter. A shift table from baseline to each visit up to Week 24 was produced for selected variables as described below. The shift categories for out of reference range were “Low, Normal, and High” for hematology, biochemistry, and urinalysis, and “Normal and Abnormal” for urinalysis (qualitative value). A shift table describing the number and percentage of subjects shifting from non-PCSV at baseline to PCSV post-baseline at any time during treatment period was produced. The percentages were calculated from the number of subjects with available baseline values and any time post-baseline value.
Unsteadiness and Sensory Evaluation: The unsteadiness and sensory evaluations were listed and analyzed for the safety analysis population. For numbness and unsteadiness, the number and percentages of subjects with ‘present’ or ‘absent’ were summarized by each visit up to Week 24. In addition, severity was summarized for each visit with the number and percentage of subjects in each category: ‘Normal/ Mild/ Moderate /Severe.’ For this summary, the subjects with ‘Absent’ were classified and counted as ‘Normal.’ A shift table from each baseline category up to Week 24 was summarized using number and percentages. Vibratory sensation values and change from baseline to each analysis visit window were summarized descriptively for right and left side of the ankle.
Columbia Suicide Severity Rating Scale (C-SSRS): The C-SSRS was analyzed and listed for the safety analysis population. The frequency and percentage of subjects with each response for suicidal ideation, intensity of ideation, and suicidal behavior items were summarized for subjects’ lifetime history (Screening to past 3 months, screening to lifetime) and during the treatment period (Weeks 12 to since last visit, Week 24 to since last visit). The distribution of responses for most severe suicidal ideation and suicidal behavior were also presented for lifetime history and the treatment period.
Percent Predicted Forced Vital Capacity (%FVC): The %FVC values and change from baseline to each post-baseline visit up to Week 24 was listed, plotted, and analyzed. The changes from baseline and their associated 95% CI were estimated separately for each visit, from the same MMRM analysis using LSMEANS estimates. In addition, frequency counts and percent for categorical %FVC (70% ≤%FVC, 50% <%FVC<70%, and %FVC ≤50%) were displayed at each visit.
For safety summaries, only observed data was used. Missing safety data was not imputed.
Subgroup analysis was performed for the following parameters:
N/A
For exploratory efficacy analysis, continuous data were summarized at each analysis visit using summary statistics. Absolute values and changes from baseline were presented. All categorical endpoints were summarized at each analysis visit, using frequency tabulations.
As the primary purpose of this study was to explore the safety of edaravone and not to perform confirmatory analyses, there was no formal hypothesis testing performed and adjustments for multiplicity were not required.
The ALSFRS-R score of each item, domain score, and total score were listed. The ALSFRS-R total score and change from baseline to each post-baseline visit up to Week 24 were plotted by visit.
The changes from baseline to all post-baseline visits until Week 24 in the ALSFRS-R score were estimated using a mixed model for repeated measures (MMRM) analysis. The model included response data from all post-baseline visits with no imputation for missing data. The ALSFRS-R score at baseline, previous exposure to edaravone, concomitant riluzole, and visit at Weeks 4, 12, and 24 were included as fixed factors in the model. An unstructured covariance structure was assumed, and the denominator degrees of freedom was computed using the Kenward-Roger method.
In case the model did not converge with the unstructured covariance structure, the heterogeneous compound symmetry (CSH) and the heterogeneous Toeplitz structure (TOEPH) were to be used instead (in that order). The changes from baseline and their associated 95% Cis were estimated, separately for each visit, from the same MMRM analysis using LSMEANS estimates.
The time to first occurrence of death, tracheostomy, or permanent assisted mechanical ventilation were derived as follows:
The following parameters were listed, plotted using Kaplan-Meier (KM) methods, and summarized by KM methods with 95% CI, the number of events and percentage.
Data for the efficacy analysis was not imputed.
Subgroup analysis was performed for the following parameters:
N/A
The Enrolled Population included 185 subjects (85.6% of all screened subjects) and the Safety Analysis Population included 185 subjects (100.0% of the Enrolled Population). The PK Analysis Population included 39 subjects (21.1% of the Enrolled Population).
A total of 216 subjects were screened, of which 185 (85.6%) subjects were enrolled and 31 (14.4%) subjects were screen failures. Reasons for screen failure included study entry criteria not met (25 [11.6%] subjects), COVID-19 (4 [1.9%] subjects), and withdrawal by the subject (2 [0.9%] subjects).
A total of 160 (86.5%) subjects in the Enrolled Population completed the 24-week study period. Of the 24 (13.0%) subjects who discontinued, the most frequent reasons for discontinuation were withdrawal by the subject (8 [4.3%] subjects), adverse event (7 [3.8%] subjects), and death (6 [3.2%] subjects). One additional subject completed the 24-week study period but did not return to the site for Week 24 procedures. The subject disposition is outlined in Table 15.
The Safety Analysis Population consisted of 185 subjects who received at least 1 dose of study drug. Overall mean treatment compliance was 99.55% (SD 5.34%), ranging from 28.6% to 103.1%. One subject (0.5%) had compliance <80%, and no subjects had compliance >120%. The mean exposure to edaravone was 61.3 days and the total exposure was 31.1 person years.
3 subjects took 4 medications during the 24-week study period that were not reported until after database lock for the 24-week analysis. One subject took Movicol for an AE of constipation, 1 subject took ketoconazole and terbinafine hydrochloride for an AE of eczema, and 1 subject took esomeprazole magnesium hydrate for gastritis prophylaxis. The majority of subjects reported concomitant use of riluzole (161 [87.0%] subjects).
Study MT-1186-A01 was designed to evaluate the safety and tolerability of oral edaravone in subjects with ALS over 24 and 48 weeks, and an exploratory objective to evaluate the efficacy of oral edaravone in subjects with ALS over 24 and 48 weeks was also established. The clinical study report currently describes the analysis at 24 weeks, with the 48-week data expected in the second quarter of 2022. The duration of the study for individual subjects will be approximately 51 weeks, consisting of a screening period of up to 3 weeks, an open-label treatment period of up to 48 weeks, and a safety follow-up period of 2 weeks after the last dose.
At 24 weeks, TEAEs were experienced by 146 (78.9%) subjects. Of these, 60 TEAEs related to study treatment (none were severe) were reported by 36 (19.5%) subjects, 30 severe TEAEs were reported by 17 (9.2%) subjects, 17 TEAEs leading to study treatment discontinuation were reported by 11 (5.9%) subjects, and 6 TEAEs leading to death were reported in 6 (3.2%) subjects. A total of 24 TESAEs were reported by 21 (11.4%) subjects. After the 24-week database lock, 7 subjects reported TEAEs that occurred during the 24-week study period. None of these TEAEs were severe, serious, related to study drug, or led to discontinuation or death. An overall summary of TEAEs is provided in Table 16.
The most commonly reported TEAEs by system organ class (SOC) were musculoskeletal and connective tissue disorders (66 [35.7%] subjects); injury, poisoning, and procedural complications (49 [26.5%] subjects); and gastrointestinal disorders (48 [25.9%] subjects). The most commonly reported TEAEs by preferred term (PT) were muscular weakness (30 [16.2%] subjects), fall (29 [15.7%] subjects), and fatigue (14 [7.6%] subjects). A summary of common TEAEs is provided in Table 17.
A total of 36 (19.5%) subjects reported a TEAE related to study drug. The most commonly reported TEAEs related to study drug by SOC were nervous system disorders (11 [5.9%] subjects), gastrointestinal disorders (9 [4.9%] subjects), musculoskeletal and connective tissue disorders (6 [3.2%] subjects), and general disorders and administration site conditions (6 [3.2%] subjects). The most commonly reported TEAEs related to study drug by PT were fatigue (6 [3.2%] subjects), dizziness (5 [2.7%] subjects), and headache (4 [2.2%] subjects).
Deaths: Six (3.2%) subjects died during the study period: 3 (1.6%) subjects died from respiratory failure and 1 (0.5%) subject died each from pneumonia, completed suicide, and ALS.
A total of 21 (11.4%) subjects reported a treatment-emergent serious adverse events (TESAE). The most frequently reported TESAEs by SOC were respiratory, thoracic, and mediastinal disorders (9 [4.9%] subjects); nervous system disorders (5 [2.7%] subjects); and infections and infestations (3 [1.6%] subjects). The most frequently reported TESAEs by PT were ALS (5 [2.7%] subjects), dyspnea (3 [1.6%] subjects), and respiratory failure (3 [1.6%] subjects). No TESAEs were related to study drug, as determined by the Investigator.
A total of 11 (5.9%) subjects reported a TEAE leading to study treatment discontinuation. Three (1.6%) subjects reported respiratory, thoracic, and mediastinal disorders leading to discontinuation. No other TEAE by SOC of PT was reported by >2 subjects.
Cardiac disorders were reported in eight subjects. Of the cardiac TEAEs reported, 2 subjects with atrial fibrillation and 1 subject each with cardiac failure, sinus arrhythmia, sinus tachycardia, supraventricular tachycardia, tachycardia, ventricular extrasystoles, tachyarrhythmia, ECG signs of ventricular hypertrophy, and ECG signs of myocardial infarction were included. Other than 1 TEAE of cardiac failure, these cardiac events arose from ECG findings. The cardiac TEAEs did not reveal a signal of concern. Most of the cardiac TEAEs were asymptomatic ECG findings or were confounded by medical history or concurrent AEs.
Clinical Laboratory Evaluation: No clear trends over time were observed for safety laboratory parameters, and There were no clear trends in terms of the number of subjects with shifts from normal to abnormal values for most safety laboratory parameters. In the Safety Analysis Population, the following AEs related to laboratory parameters were reported:
Vital Signs: Summaries of vital signs by visit and change from baseline by visit and by visit and region were collected. Overall, all vital signs were stable, and there were no notable trends during the study.
Electrocardiogram: Data on 12-lead ECG parameters and change from baseline by visit and by visit and region were collected. Distribution of out-of-normal range values of 12-lead ECG by visit and by visit and region is provided in and shifts of potentially clinically significant 12-Lead ECGs by region were recorded. There were no notable trends in 12-lead ECG parameters.
Physical Examination: There were no notable trends seen during physical examination in any group during the study. However, in the Safety Analysis Population, 6 (3.2%) subjects reported a TEAE of weight decreased.
Unsteadiness and Sensory Evaluation: Data for numbness and unsteadiness with severity was collected at each visit. Shifts from baseline in numbness and unsteadiness at each visit was also recorded, as was vibratory sensation information. No notable trends were observed during the study.
Columbia-Suicide Severity Rating Scale (C-SSRS): Summary information from C-SSRS administered to subjects was gathered, and no notable trends in suicidal ideation or behavior were observed during study treatment.
Forced Vital Capacity Percentage: At baseline, mean %FVC was ||||% (SD ||||%). The LS mean change from baseline was ||||% (95% CI |||||||||) at Week 4, ||||% (95% CI ||||||||||) at Week 12, and |||||% (95% CI -||||||||||) at Week 24.
Study drug was generally well tolerated. TEAEs were experienced by 146 (78.9%) subjects. Of these, 60 TEAEs related to study treatment were reported by 36 (19.5%) subjects, 30 severe TEAEs were reported by 17 (9.2%) subjects, 17 TEAEs leading to study treatment discontinuation were reported by 11 (5.9%) subjects, and 6 TEAEs leading to death were reported in 6 (3.2%) subjects. A total of 24 TESAEs were reported by 21 (11.4%) subjects.
The most commonly reported TEAEs by SOC were musculoskeletal and connective tissue disorders (66 [35.7%] subjects); injury, poisoning, and procedural complications (49 [26.5%] subjects); and gastrointestinal disorders (48 [25.9%] subjects). The most commonly reported TEAEs by PT were muscular weakness (30 [16.2%] subjects), fall (29 [15.7%] subjects), and fatigue (14 [7.6%] subjects).
Six (3.2%) subjects died during the study period: 3 (1.6%) subjects died from respiratory failure and 1 (0.5%) subject died each from pneumonia, completed suicide, and ALS. The most frequently reported TESAEs by SOC were respiratory, thoracic, and mediastinal disorders (9 [4.9%] subjects); nervous system disorders (5 [2.7%] subjects); and infections and infestations (3 [1.6%] subjects). The most frequently reported TESAEs by PT were ALS (5 [2.7%] subjects), dyspnea (3 [1.6%] subjects), and respiratory failure (3 [1.6%] subjects). No TESAEs or severe TEAEs were related to study drug, as determined by the Investigator. ALS is known to be associated with respiratory complications.
No trends were observed in safety laboratory parameters, vital signs, 12-lead ECGs, or physical examinations. Percentage of the predicted FVC decreased over the study period.
The most frequently reported TEAEs, TESAEs, and TEAEs leading to death were associated with ALS disease progression or were non-specific symptoms, and no unique safety concerns were identified in the results of the MT-1186-A01 study.
The exploratory efficacy analysis evaluated the functional and survival assessments of oral edaravone efficacy. This evaluation was secondary to the main safety analysis.
At baseline, the mean ALSFRS-R total score was 40.0 (SD 4.5). The change from baseline in LS mean ALSFRS-R score at Week 4, Week 12, and Week 24 was −0.8 (95% CI −1.3 to −0.4), −3.0 (95% CI −3.7 to −2.4), and −5.6 (95% CI −6.5 to −4.8), respectively. The LS mean score of each domain decreased over the 24 weeks. ALSFRS-R results and changes from baseline by visit for the Safety Analysis Population are provided in Table 18.
Time to Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation: A summary of number (%) and time to death, tracheostomy, or permanent assisted mechanical ventilation up to the last observed visit for the Safety Analysis Population is provided in Table 19. Six (3.2%) subjects died during the study period. No subjects received a tracheostomy or permanent assisted mechanical ventilation during the study period. Time to death, tracheostomy, or permanent assisted mechanical ventilation was not calculated for these subjects.
CADTH conducted a critical appraisal of the clinical studies for edaravone oral suspension based on the summary of the evidence provided by the sponsor.
The most significant limitation associated with the included trials is the study designs. The bioequivalence design in healthy participants and the open-label uncontrolled study are not sufficient to evaluate the comparative clinical value added for the drug in the target population for reimbursement. The key assumption of the submission is that as IV edaravone has been approved by Health Canada and recommended for reimbursement by CADTH, establishing bioequivalence is sufficient to establish the clinical value of oral edaravone. However, the 2 formulations (solution for injection and oral suspension) cannot be considered bioequivalent since they involve 2 different dosing forms. Whether they can be considered to display comparable bioavailability of edaravone upon administration is to be assessed by Health Canada during formal review. While there is merit and supporting precedent to the assumption of comparable bioavailability, there remains a degree of uncertainty as to the true treatment effects of oral edaravone given the bioequivalence study design (i.e., single administration, assessing pharmacokinetic parameters with estimates falling within a range of acceptable values to establish equivalence) and the lack of comparative evidence between the oral and IV formulations’ effects on clinical outcomes.
Since safety study MT-1186-A01 was an uncontrolled trial, it was not designed to inform on the comparative efficacy of oral edaravone, even if this was a secondary outcome of the trial. With the previous establishment of efficacy for IV edaravone in the treatment of ALS, the sponsor did not consider it appropriate to include a comparative placebo control group.
Patients were randomly allocated to 1 of the 2 treatment groups of the open-label, single-dose study MT-1186-J03 using a randomization key code table. No patient withdrew from the trial. Baseline characteristics were balanced between treatment groups.
Study MT-1186-A01 was an open-label, uncontrolled trial. Therefore, randomization and allocation concealment — 2 important strategies to minimize biases in clinical trials — do not apply here, subjecting the study to a high risk of bias and limiting the conclusions that can be drawn from the study. After a follow-up period of 24 weeks, 13% of patients had withdrawn from the study, which did not lead to any particularly significant concerns.
The bioequivalence and pharmacokinetic parameters measured in study MT-1186-J03 are considered appropriate, objective, and reliable outcome measures; however, 2 different drug formulations (solution for injection and oral suspension) with 2 different dosing forms cannot be considered bioequivalent, although they may display comparable bioavailability after administration. This is not for CADTH to evaluate, but for Health Canada to assess during formal review. The patient-reported outcomes such as AEs in study MT-1186-A01 are considered more subjectively measured outcomes, especially in the context of an open-label trial.
In study MT-1186-A01, efficacy was a secondary exploratory outcome assessed using the ALSFRS-R. The ALSFRS-R is a well-studied tool with demonstrated construct validity and internal consistency reliability, its use being supported by the FDA as a measure of treatment effect on function in daily living.51 However, the respiratory subscale does not correlate strongly with percent FVC, and the minimal clinically important difference for the slope of the ALSFRS-R score over time is based on expert opinion, leading to a degree of subjectivity in the items. More importantly, the trial did not include a control group, preventing adequate assessment of the real effect of the drug on the natural history of the disease over time.
For assessment with the bioequivalence limit in study MT-1186-J03, analysis of variance was conducted on the following pharmacokinetic parameters: AUC0-t, AUC0-∞, and Cmax. The estimated 90% CIs of the geometric mean ratios were examined, and if they lay entirely within the limits of 0.80 and 1.25, then the bioequivalence between IV formulation and oral suspension was concluded. The analysis was performed by analysis of variance, which included factors accounting for the following sources of variation: sequence, subjects nested in sequences, period, and treatment.
Study MT-1186-A01 evaluated the safety and tolerability of edaravone using descriptive statistics in the absence of a control group.
Study MT-1186-J03 was performed with healthy individuals who identified as Japanese and had no medical history or complications at baseline. Selection of healthy volunteers is typical of bioequivalence studies, but the population is not representative of the real-life patients for whom edaravone is intended. This would not, however, significantly impact the confidence in the results.
Inclusion and exclusion criteria appeared relevant and reasonable in study MT-1186-A01. The trial included adult patients with ALS living and functioning independently whose first symptom of ALS had occurred within the previous 3 years and who had a baseline FVC greater than or equal to 70%. Some categories of patients were excluded, such as patients with an FVC less than 70%, patients who require the assistance of others for daily function, and patients with ALS symptom onset more than 3 years ago. Therefore, the findings are not generalizable to these categories of patients.
In both studies, the dosage of edaravone was aligned with the Health Canada–approved dosing. Study MT-1186-J03 was a single-dose study to assess bioequivalence, thus justifying the short follow-up duration. In study MT-1186-A01, the administration schedule of edaravone was aligned with the Health Canada product monograph. The study planned to follow patients for 48 weeks; however, results submitted to CADTH described the analysis at 24 weeks, since the 48-week data were not yet available at the time of the Reimbursement Review. There was no information reported as to how issues related to interim analyses were handled, such as the adequacy of type I error rate control across multiple time points and the appropriateness of methods used to maintain trial integrity with interim analyses.
That 87% of patients took riluzole in study MT-1186-A01, which was allowed throughout the trial duration, is representative of clinical practice. However, its use also acts as a confoundant, with the result being that AEs reported in the study may also be attributable to the concomitant medication.
The choice of outcome measures for assessing bioequivalence in study MT-1186-J03 was considered adequate. Harms outcomes were also assessed appropriately in study MT-1186-A01 with the use of AEs as the primary outcome measure.
However, no comparative data were reported for the outcomes of motor function, mobility, muscle pain, and fatigue, as well as difficulty breathing and speaking, which were identified by patients with ALS as the most important symptoms to control according to the patient input received. This is an important gap in the evidence.
The sponsor submitted a cost comparison of oral edaravone to IV edaravone for the treatment of ALS. At the submitted price of $9,200 per 1,050 mg of edaravone per 50 mL of suspension or $12,880 per package of two 735 mg (35 mL) bottles, the annual cost per patient of treatment with oral edaravone is $123,280 in the first year and $119,600 per subsequent year (Table 20), excluding markups and dispensing fees. When comparing drug costs alone, the annual cost of therapy with oral edaravone is the same as that of IV edaravone at Ontario Drug Benefit Exceptional Access Program list prices.
When also considering IV administration and AE costs, the sponsor estimated that IV edaravone would be associated with an average of |||||| per patient per year in AE-related hospitalization costs as well as an average of ||||||||| per patient per year in IV infusion costs (e.g., catheter insertion, maintenance, and removal), for a total of ||||||||| per patient per year in health care costs (Table 21). CADTH notes that the sponsor has accounted for the proportion of these costs covered by its PSP. Further detail on these costs can be found in Table 23. As oral edaravone would not be associated with these costs, the sponsor concluded that the use of oral edaravone would result in a saving of ||||||||| per patient per year.
CADTH revised the sponsor’s analysis to consider costs in subsequent years in addition to those in the first year of therapy. CADTH used the sponsor’s provided inputs (Table 21, Table 23) to recalculate the incremental savings associated with oral edaravone compared to IV edaravone arising from IV administration and IV-related AEs. For the first year of therapy, CADTH reanalysis was aligned with the sponsor’s in that oral edaravone was associated with a weighted average savings of $1,561 in administration costs and $89 in IV-related AE costs, for a total average incremental savings of $1,649 per patient compared to IV edaravone. For subsequent years, the CADTH reanalysis suggests that oral edaravone was associated with an average saving of $1,016 in administration costs and $89 in IV-related AE costs, for a total average incremental saving of $1,105 per patient per year.
CADTH was unable to account for uncertainties in the comparative effectiveness and safety between edaravone products or for the confidential pricing and stipulations that may have been negotiated for IV edaravone.
To inform on the use of oral edaravone compared to its IV formulation, 2 manufacturer-sponsored studies were included in this review.
The single-dose, randomized, open-label bioequivalence study MT-1186-J03 (n = 42)8,9 evaluated the bioequivalence of an oral suspension and an IV formulation of edaravone in healthy individuals who identified as Japanese. The key outcomes were the pharmacokinetic parameters of AUC and Cmax.
The second study was a multicentre, open-label, single-group study, MT-1186-A01 (n = 185),10 that evaluated the longer-term safety and tolerability of oral edaravone in patients with ALS living and functioning independently whose first symptom of ALS had occurred within the previous 3 years and who had a baseline FVC greater than or equal to 70%. At the time of the review, the 24-week results were available. Patients received edaravone as a 105 mg oral suspension administered in accordance with the Health Canada–approved regimen. The concomitant use of riluzole was permitted throughout the study.
Based on the sponsor’s analysis, results from the single-dose, randomized, open-label bioequivalence study MT-1186-J03 show that an oral suspension of edaravone 105 mg was equivalent to an IV formulation of edaravone 60 mg in healthy volunteers who identified as Japanese. In this analysis, oral edaravone had equivalent AUC0-t and AUC0-∞ of unchanged edaravone compared to the IV formulation, as both geometric mean ratio and 90% CI were within the range of 0.80 to 1.25. As for Cmax, the geometric mean ratio and its lower limit of the 90% CI were also within the prespecified limits, while the upper limit of the 90% CI exceeded 1.25.
An exploratory efficacy analysis was reported in the open-label, single-group study MT-1186-A01, evaluating the functional assessment of oral edaravone efficacy using the ALSFRS-R. The least squares mean score of each domain decreased over the 24 weeks. The change from baseline in least squares mean in the ALSFRS-R score at week 4, week 12, and week 24 was –0.8 (95% CI, –1.3 to –0.4), –3.0 (95% CI, –3.7 to –2.4), and –5.6 (95% CI, –6.5 to –4.8), respectively. The ALSFRS-R is a well-studied tool with demonstrated construct validity and internal consistency reliability and is supported by the FDA as a measure of treatment effect on function in daily living. However, the level of confidence in the evidence is highly affected by several limitations, most importantly the open-label uncontrolled trial design of the study that introduces a high risk of bias. Therefore, no efficacy conclusions could be drawn from these findings.
The key assumption of the submission hinges on the previous recommendation that IV edaravone be reimbursed for the treatment of ALS (with conditions) and on oral edaravone being bioequivalent to the IV formulation. The finding of bioequivalence would establish the clinical effectiveness of the oral formulation relative to the IV 1. However, the 2 formulations (solution for injection and oral suspension) cannot be considered bioequivalent since they involve 2 different dosing forms. Whether they can be considered to display comparable bioavailability of edaravone upon administration is to be assessed by Health Canada during formal review. While bioavailability is an accepted approach for market access, it makes it difficult to determine the clinical value of the product in the absence of comparative assessments with clinically important outcomes in ALS. This is in part because the population in which the comparable bioavailability was established was in healthy participants, not in those with ALS. In addition, comparable bioavailability may be claimed based on an established range in which pharmacokinetic values may fall, and therefore there will be a range of treatment effects in practice settings, which is particularly notable in a disease that has a heterogeneous natural history. Although the interventional study, MT-1186-A01, examined clinical outcomes, no concrete conclusions could be drawn because of the aforementioned limitations of the study. Therefore, while it is accepted that oral edaravone appears to display comparable bioavailability to the IV formulation, there remains uncertainty as to what the true treatment effect will be in Canadian patients with ALS.
Additionally, the submission highlighted the difficult administration of IV edaravone and that the oral formulation provides an option for patients to avoid the issues surrounding IV administration. Indeed, both patient and clinician input to CADTH specified many issues with the IV administration. According to the clinical expert consulted by CADTH, the uptake of IV edaravone has so far been low, in part because the IV formulation is invasive and comes with a time-consuming administration schedule. The clinical expert believed that the oral formulation would be a well-received alternative, as many patients choose not to embark on the currently available IV formulation because of the caveats and excessive requirements and constraints related to IV infusion. Indeed, the patient input received highlighted the difficulties related to the IV administration of edaravone, including patients having to schedule activities of daily living around their infusion schedule and needing to have a port catheter implanted. Both the drug plans and the clinical expert noted in their inputs that an oral version of edaravone would be a lot easier for patients to access than its IV formulation, reducing the risk of exposure to unnecessary infusion-associated AEs and decreasing health care system burden related to the IV administration. No comparative data were provided regarding outcomes like patient preference or improved treatment adherence between the 2 modes of administration.
One patient in each treatment group reported an AE of mild intensity in the single-dose bioequivalence study MT-1186-J03; these AEs were not judged to be reasonably related to the investigational products by the investigator. No SAEs, no withdrawals due to AEs, and no AEs of special interest were reported in the study.
Results from the single-group safety study MT-1186-A01 in patients with ALS were reported for the 24-week interim analysis. Seventy-nine percent of patients experienced at least 1 AE; however, discontinuation due to AEs was low (6%), suggesting the harm profile might be considered acceptable. SAEs were reported by ||| of patients; the most frequently reported were ||||||||||||||||||||||||||||||||||||||||||||||||||| patients died over the 24-week study period; causes of death were ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||. There is no evidence to assess the comparative AE profiles of IV edaravone and oral edaravone. Information reported in the Health Canada draft product monograph7 and in the CADTH Reimbursement Review for IV edaravone28 suggests that the oral version is not associated with an increased incidence of AEs.
At the submitted price of $9,200 per 1,050 mg of edaravone per 50 mL of suspension or $12,880 per package of two 735 mg (35 mL) bottles, the annual drug cost per patient of treatment with oral edaravone is $123,280 in the first year and $119,600 per subsequent year, which is equivalent to the drug acquisition cost of IV edaravone at publicly available prices. CADTH conducted a reanalysis of the sponsor-submitted cost comparison, considering that costs associated with IV administration and IV-related AEs differ in the first and subsequent years of therapy. In this analysis, where some of the IV administration costs were assumed to be borne by the sponsor’s PSP, oral edaravone was associated with an average cost saving to the public health care payer of $1,649 per patient compared to IV edaravone in the first year of therapy, and $1,105 per patient in subsequent years of therapy.
The cost comparison assumes clinical similarity between the oral and IV formulations of edaravone, based on the sponsor’s submitted single-dose bioequivalence study and an uncontrolled, open-label safety study. CADTH was unable to account for uncertainties in the comparative clinical effectiveness and safety between edaravone products or for the confidential pricing and stipulations that may have been negotiated for IV edaravone.
Findings from the sponsor’s analysis of bioequivalence suggested that oral edaravone showed comparable bioavailability to its IV formulation in a population of healthy volunteers; however, this requires formal assessment by Health Canada. Since IV edaravone was found to slow the rate of decline in motor function in patients with ALS, comparable bioavailability would suggest that the same conclusion may apply to oral edaravone. Findings from a single-group safety study suggest that the harms profile of oral edaravone may be considered acceptable, and no major safety signal was identified. However, the level of confidence in the evidence is highly affected by several limitations including the open-label uncontrolled trial design of the study, which introduced a high risk of bias. The lack of comparative data with oral edaravone for the outcomes of motor function, mobility, muscle pain, and fatigue, as well as difficulty breathing and speaking, which were identified by patients with ALS as the most important symptoms to control according to the patient input received, remains a gap in the evidence. Input received from all sources, including patients with ALS, clinicians, and the clinical expert consulted by CADTH for this review, emphasized that an oral version of edaravone would be a lot easier for patients to access than its IV formulation, reducing the risk of exposure to unnecessary infusion-associated AEs and decreasing the burden related to IV administration both to the health care system and to patients with ALS themselves.
At the submitted price, the annual drug cost of oral edaravone is $123,280 per patient in the first year and $119,600 per patient in subsequent years, which is the same as the annual drug cost of IV edaravone. When costs associated with IV administration and IV-related AEs are considered, and the sponsor’s PSP which funds some IV administration costs is taken into account, oral edaravone is $1,649 less expensive per patient than IV edaravone in the first year, and $1,105 less expensive in subsequent years. The results are based on publicly available list prices for IV edaravone and may not reflect actual prices paid by Canadian public drug plans.
adverse event
amyotrophic lateral sclerosis
ALS Functional Rating Scale — Revised
area under the plasma concentration–time curve
area under the plasma concentration–time curve from zero up to the last quantifiable concentration time point
area under the plasma concentration–time curve from zero up to infinity with extrapolation of the terminal phase
maximum plasma concentration after administration
Canadian ALS Research Network
CADTH Canadian Drug Expert Committee
confidence interval
forced vital capacity
lower motor neuron
patient support program
serious adverse event
standard deviation
upper motor neuron
Note that this appendix has not been copy-edited.
Note that this appendix has not been copy-edited.
In the submitted budget impact analysis (BIA), the sponsor assessed the budgetary impact of reimbursing oral edaravone for the treatment of ALS compared to the reference scenario in which considered IV edaravone only. The BIA was conducted from a Canadian drug plan payer perspective over a 3-year time horizon (2023 to 2025) using an epidemiological approach and included drug acquisition costs. The sponsor also submitted a scenario analysis from a health care payer perspective which considered drug acquisition costs as well as administration costs associated with peripherally inserted central catheter line or implantable port insertion and maintenance for IV edaravone, and costs associated with IV-site infections and infusion site thrombosis. Data for the model was obtained from: Statistics Canada,32 the NIHB annual report,33 real-world data from the sponsor’s PSP (not provided), the sponsor’s internal projections, the Ontario Case Costing Initiative,29 and formulary-specific costs.30,34 Key inputs to the BIA are documented in Table 25.
Key assumptions included:
The sponsor’s base case reported that the reimbursement of oral edaravone for the treatment of ALS would be associated with an incremental cost of $2,597,291 in Year 1, $4,521,761 in Year 2, and $6,651,801 in Year 3, for a 3-year total incremental budget impact of $13,770,852. When other health care costs were considered, i.e., IV administration and IV-related AEs, the reimbursement of oral edaravone would be associated with a 3-year total incremental budget impact of $13,494,762.
CADTH identified several key limitations to the sponsor’s analysis that have notable implications on the results of the BIA:
CADTH revised the sponsor’s submitted analyses by ensuring the NIHB population was not double counted, increasing the market uptake of edaravone, and increasing the proportion of edaravone patients using the oral formulation. The changes applied to derive the CADTH base case are described in Table 26.
The results of the CADTH step-wise reanalysis are presented in summary format in Table 27 and a more detailed breakdown is presented in Table 28. When considering the drug plan payer perspective, CADTH reanalyses suggest that reimbursement of oral edaravone will be associated with a 3-year budgetary incremental cost of $38,710,109. When a health care payer perspective is taken, CADTH reanalyses suggest the resulting 3-year budgetary incremental cost of reimbursing oral edaravone would be slightly reduced to $38,359,198.
Results of the BIA are highly dependent on the estimated increase in the proportion of ALS patients using edaravone due to the reimbursement of the oral formulation. CADTH therefore conducted a scenario analysis assuming a reduced overall uptake of edaravone of 12%, 16%, and 20% in years 1, 2, and 3, respectively. CADTH also conducted a scenario assuming that 65% of edaravone patients would be publicly reimbursed to explore uncertainty in the proportion of patients covered by public drug plans. See Table 28.
c Shimizu H, Nishimura Y, Shiide Y, et al., 2021
.&p=BOOKS&id=601773_SR0727-fig02.jpg "Click on image to zoom")
%20Sulfate%20Conjugate%20and%20(B)%20Glucuronide%20Conjugate%20for%20Both%20Oral%20Suspension%20(105mg)%20and%20IV%20Formulation%20(60mg)%20of%20Edaravone.&p=BOOKS&id=601773_SR0727-fig03.jpg "Click on image to zoom")
ET = early termination; EOT = end-of-treatment; EOS = end-of-study.
Note: Figure was redacted upon the sponsor request
j Study MT-1186-A01 Week 24 Clinical Study Report (CSR)
| Item | Description |
|---|---|
| Drug product | Edaravone oral suspension (Radicava), 105 mg per 5 mL of suspension |
| Indication | Treatment of patients with amyotrophic lateral sclerosis |
| Reimbursement request | As per indication |
| Health Canada approval status | NOC |
| Health Canada review pathway | Priority review |
| NOC date | November 8, 2022 |
| Sponsor | Mitsubishi Tanabe Pharma Canada, Inc. |
NOC = Notice of Compliance.
| Confirmatory plasma pharmacokinetic parameters | Geometric least squares mean | Oral over IV ratio (90% CI) | |
|---|---|---|---|
| Oral | IV | ||
| Cmax (ng/mL) | 1,500 | 1,232 | 1.217 (1.090 to 1.359) |
| AUC0-t (ng·h/mL) | 1,645 | 1,689 | 0.974 (0.914 to 1.038) |
| AUC0-∞ (ng·h/mL) | 1,665 | 1,704 | 0.977 (0.917 to 1.041) |
AUC0-t = area under the plasma concentration–time curve from zero up to the last quantifiable concentration time point; AUC0-∞ = area under the plasma concentration–time curve from zero up to infinity with extrapolation of the terminal phase; CI = confidence interval; Cmax = maximum plasma concentration after administration.
Source: MT-1186-J03 Clinical Study Report.8
| AEs | Oral edaravone (N = 185) |
|---|---|
| AEs, n (%) | 146 (78.9) |
| Most frequently reported AEs | |
| Muscular weakness | 30 (16.2) |
| Fall | 29 (15.7) |
| Fatigue | 14 (7.6) |
| Back pain | 13 (7.0) |
| Constipation | 13 (7.0) |
| Headache | 11 (5.9) |
| Dyspnea | 10 (5.4) |
| SAEs, n (%) | 21 (11.4) |
| WDAEs, n (%) | 11 (5.9) |
| Deaths, n (%) | 6 (3.2) |
| AEs of special interest, n (%) | |
| Cardiac disorders | 8 (4.3) |
AE = adverse event; SAE = serious adverse event; WDAE = withdrawal due to adverse event.
Source: MT-1186-A01 Week 24 Clinical Study Report.10
| Characteristic | Edaravone | Riluzole |
|---|---|---|
| Mechanism of action | The mechanism by which edaravone exerts its therapeutic effect in patients with ALS is unknown. | The mode of action of riluzole is unknown, though its pharmacological properties include the following:
|
| Indicationa | Treatment of patients with amyotrophic lateral sclerosis | May extend survival and/or time to tracheostomy in some patients with ALS |
| Route of administration | IV or oral | Oral |
| Recommended dose | IV infusion of 60 mg administered over a 60-minute period, according to the following schedule:
| One 50 mg tablet every 12 hours |
| Serious side effects or safety issues | Hypersensitivity reactions (redness, weals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported in spontaneous postmarketing reports | Riluzole is contraindicated in patients who have hepatic disease or who have baseline transaminases > 3 times the upper limit of normal |
| Drug program implementation questions | Clinical expert response |
|---|---|
| Relevant comparators | |
| Would the submitted trials be sufficient to state similar efficacy or effectiveness between the oral and IV versions of edaravone? | The clinical expert considers that the submitted trials would be sufficient to show comparable bioavailability and that there is no reason to think that the efficacy profiles of the 2 versions would differ. |
| Edaravone IV was previously reviewed by CDEC in 2018/2019, with the final recommendation (positive) posted March 27, 2019. IV edaravone is a restricted benefit in most jurisdictions. | For CDEC consideration. |
| Considerations for initiation of therapy | |
| The sponsor is requesting a recommendation for patients with ALS with the same criteria as IV edaravone. Consider stating in the criteria something similar to “reimburse in a similar manner as IV edaravone.” Would CDEC consider updating the previous recommendation for IV edaravone with recommendation of this new formulation? Or would the oral formulation and the data presented be considered for a new recommendation? | For CDEC consideration. |
| Considerations for prescribing of therapy | |
| Similar concerns related to accessing clinical specialists and/or special settings for IV edaravone. | For CDEC consideration. According to the clinical expert, ALS should be managed by a specialist and a multidisciplinary team. It is the clinical expert’s opinion that there is sufficient access to ALS specialists across the country and that there is no need to expand to family doctors. The clinical expert considers that delaying introduction of treatment with edaravone is unlikely to significantly affect patients’ trajectory. The clinical expert expects easier access for patients to the oral version of edaravone. Access to IV administration and semipermanent catheter insertion is an issue depending on where someone lives, which is why having an oral option makes it a lot easier for patients to receive appropriate treatment. |
| The prescribing criterion with IV edaravone was: Patient must be under the care of a specialist with experience in the diagnosis and management of ALS. Consider alignment of prescribing criteria with IV edaravone, especially given the trials submitted? | For CDEC consideration. According to the clinical expert, ALS should be managed by a specialist and multidisciplinary team. It is the clinical expert’s opinion that there is sufficient access to ALS specialists across the country and that there is no need to expand to family doctors. The clinical expert considers that delaying introduction of treatment with edaravone is unlikely to significantly affect patients’ trajectory. The clinical expert also noted that the initial prescription and subsequent renewals should happen through specialty clinics. Ongoing management of patients is optimal when performed by a specialized multidisciplinary team rather than through a family doctor. |
| Care provision issues | |
| The oral formulation could be a treatment option for new patients (treatment naive). The oral formulation is a possible option for patients on IV edaravone to switch to p.o. edaravone (treatment experienced). Initial treatment cycle: There is a starter kit that contains two 35 mL bottles that provide daily dosing for 14 days followed by a 14-day drug-free period. Subsequent treatment cycle: Daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods (1 bottle of 50 mL). Note: Discard 15 days after opening bottle or, if unopened, 30 days from date of shipment indicated on the carton pharmacy label. The administration schedule for edaravone is complex. For IV use, patients would undergo 134 infusions in the first year and 130 infusions in subsequent years in a dedicated administration clinic or hospital. The oral formulation, administered via mouth or feeding tube, would target the same patient population (e.g., at home). Same sponsor as IV; therefore, the transition to p.o. may be seamless for patients currently on IV. How would patients access this product (e.g., specialty pharmacy, hospital pharmacy)? | The clinical expert indicated that an oral version of edaravone would be a lot easier to access than its IV formulation, likely resulting in a displacement of the IV formulation. The clinical expert expects that both edaravone-naive and edaravone-experienced patients would be prescribed treatment with the oral version of the product, expanding the number of patients using the medication. The clinical expert indicated that the oral formulation might be accessed in a similar manner to the IV formulation (i.e., through a specialty pharmacy). The sponsor indicated that oral edaravone will be supplied via || |||||||||||||||||||||||||||||||||||||||||||||||||||||||||. It will be delivered either at the pharmacy of choice or, through mail-order, at the location of choice for each patient and through the same patient support program as IV edaravone. |
| Oral therapy provides an option to reduce risk of exposure to unnecessary infusion-associated adverse effects. | For CDEC consideration. |
| System and economic issues | |
| May become a preferred product based on convenience and an ideal administration route (vs. IV) especially during the pandemic. The list price of edaravone p.o. is $920 per day, which the sponsor states is at parity with the IV formulation (annual cost $123,280 per patient in year 1; $119,000 per patient in subsequent years). Anticipated budget impact of $13,494,762 over 3 years due to the reduction in public health resource expenditures associated with the IV edaravone formulation, resulting in cost savings of $276,090 to public health plans. Recommend that the drug plan cost of edaravone p.o. does not exceed the drug plan cost of IV edaravone. | For CDEC consideration. |
| Oral product can decrease health system costs for administration and increase accessibility to patients. | For CDEC consideration. |
ALS = amyotrophic lateral sclerosis; CDEC = CADTH Canadian Drug Expert Committee; p.o. = orally; vs. = versus.
| Characteristic | MT-1186-J03a,b |
|---|---|
| Designs and populations | |
| Study design | A single-dose, randomized, 2-period, 2-sequence crossover, open-label phase 1 study to evaluate the bioequivalence of an oral suspension and IV formulation of edaravone in healthy subjects by assessing each PK parameter with the bioequivalence limit. |
| Locations | Japan: Single-site |
| Patient enrolment dates | March 2019 to June 2019 |
| Randomized (N) | 42 |
| Inclusion criteria |
|
| Exclusion criteria |
|
| Drugs | |
| Intervention | Edaravone oral suspension,105 mg |
| Comparator(s) | Edaravone IV formulation, 60 mg/60 min |
| Duration | |
| Phase | |
| Run-in | N/A |
| Double-blind | N/A |
| Follow-up | 7 days and 6 nights |
| Outcomes | |
| Primary end point |
|
| Secondary and exploratory end points | Reference PK parameters:
|
| Notes | |
| Publications | Shimizu H, Nishimura Y, Shiide Y, Yoshida K, Hirai M, Matsuda M, et al. Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2021;10(10):1188-97c. Provide the clinicaltrials |
Ae= volume of distribution at steady state ; Ae%= urinary excretion ratio of drug; AUC0-t= area under the plasma concentration-time curve from zero up to the last quantifiable concentration time-point; AUC0-24= area under the plasma concentration-time curve from zero up to 24 hours; AUC0-∞= area under the plasma concentration-time curve from zero up to infinity with extrapolation of the terminal phase; AUC0-all= area under the plasma concentration-time curve from zero up to the last sampling time-point (for all time-points); BMI= body mass index; CL= total clearance; CL/F= apparent total clearance after oral administration; CLr: Renal clearance; Cmax= maximum plasma concentration after administration; ECG= electrocardiogram; F= bioavailability; IV= intravenous; Kel= elimination rate constant from the central compartment; MRT= mean residence time; PO= by mouth (oral administration); t1/2= terminal elimination half-life in plasma concentration-time course; tmax= time to reach Cmax; Vz,= volume of distribution during terminal phase; Vz/F= apparent volume of distribution during terminal phase after oral administration Vss= volume of distribution at steady state; Vss/F= apparent volume of distribution at steady state after oral administration
Study MT-1186-J03 Clinical Study Report (CSR)
Study MT-1186-J03 Clinical Study Protocol
| Characteristics | PO – IV (N=21)a | IV – PO (N=21)a |
|---|---|---|
| Analysis set Safety, n (%) PK, n (%) | 21 (100) 21 (100) | 21 (100) 21 (100) |
| Sex Males, n (%) Females, n (%) | 14 (66.7) 7 (33.3) | 14 (66.7) 7 (33.3) |
| Mean age ± SD (years) | 34.5 ± 7.7 | 31.8 ± 7.0 |
| Mean height ± SD (cm) | 166.63 ± 7.58 | 167.20 ± 6.58 |
| Mean weight ± SD (kg) | 63.95 ± 8.63 | 62.76 ± 7.20 |
| Mean BMI ± SD (kg/m2) | 22.98 ± 2.07 | 22.45 ± 2.28 |
| Medical history Yes, n (%) No, n (%) | 0 (0) 21 (100) | 0 (0) 21 (100) |
| Complications Yes, n (%) No, n (%) | 0 (0) 21 (100) | 0 (0) 21 (100 |
| Concomitant medications Yes, n (%) No, n (%) | 0 (0) 21 (100) | 1 (4.8) 20 (95.2) |
| Allergic history (including drug allergies) Yes, n (%) No, n (%) | 0 (0) 21 (100) | 0 (0) 21 (100) |
| Drinking status Yes, n (%) No, n (%) | 13 (61.9) 8 (38.1) | 8 (38.1) 13 (61.9) |
| Smoking status Yes, n (%) No, n (%) | 4 (19.0) 17 (81.0) | 6 (28.6) 15 (71.4) |
BMI= body mass index; cm= centimetres; IV = intravenous; kg=kilograms; PK= pharmacokinetic; PO= by mouth, oral administration; SD= standard deviation
Study MT-1186-J03 Clinical Study Report (CSR)
| Characteristics | MT-1186-J03a | |
|---|---|---|
| PO – IV | IV – PO | |
| Subjects who gave informed consent and were screened, N | |||||||||| | |
| Screening failures, N Withdrawal of consent, N Met exclusion criteria, N Other, N |
||||||||||
|||||||||| |||||||||| |||||||||| | |
| Eligible subjects, N | |||||||||| | |
| Subjects hospitalized as prospective subjects, N | |||||||||| | |
| Reserve subjects, N | |||||||||| | |
| Total randomized, N | 42 | |
| Randomized to each group, N | 21 | 21 |
| Subjects treated with the investigational product in period I | 21 | 21 |
| Subjects withdrawn after period I, N | 0 | 0 |
| Subjects treated with the investigational product in period II | 21 | 21 |
| Subjects withdrawn after period II, N | 0 | 0 |
| Subjects completed, N | 21 | 21 |
IV= intravenous; PO= by mouth, oral administration
Study MT-1186-J03 Clinical Study Report (CSR)
| Treatmenta
(N = 42) | Plasma PK Parameter | tmax1, h | Cmax, ng/mL | AUC0-t, ng·h/mL | AUC0-∞, g·h/mL | t1/2, h | F, % | Vss, L | Vz, L | CL2, L/h |
|---|---|---|---|---|---|---|---|---|---|---|
| Oral (105mg) | Arithmetic mean | 0.5 | 1656 | 1743 | 1762 | 9.75 | 57.3 | — | — | 67.9 |
| CV% | 0.3-0.8 | 44.3 | 30.7 | 30.6 | 86.9 | 21.9 | — | — | 44.4 | |
| IV (60mg) | Arithmetic mean | 1.0 | 1253 | 1720 | 1736 | 8.82 | — | 63.1 | 418 | 35.9 |
| CV% | 1.0-1.0 | 18.3 | 18.9 | 19.1 | 94.4 | — | 34.9 | 76.7 | 20.9 | |
| CV% | 1.0-1.3 | 23.3 | 21.1 | 21 | 12.9 | — | — | — | — |
AUC=area under the plasma concentration–time curve; AUC0-∞= AUC from time 0 to infinity; AUC0-t =AUC from time 0 to the last quantifiable time point; CL= total clearance; Cmax = maximum plasma concentration after administration; CV%= coefficient of variation percentage; F =bioavailability calculated from ratio of AUC0-∞; IV= intravenous; PK = pharmacokinetic; t1/2= half-life; tmax,= time to reach Cmax; Vss, =volume of distribution at steady state; Vz = volume of distribution during terminal phase.
Median and range.
Apparent CL after oral administration.
Study MT-1186-J03 Clinical Study Report (CSR)
| Urine PK parameter | Treatment (N=42)a | Oral (105mg) | IV (60mg) |
|---|---|---|---|
| Unchanged edaravone | |||
| Ae% (% of dose) | Arithmetic mean | 0.6 | 0.9 |
| CV% | 31.7 | 29.0 | |
| CLr, L/h | Arithmetic mean | 0.4 | 0.3 |
| CV% | 53.4 | 36.6 | |
| Sulfate conjugate | |||
| Ae% (% of dose) | Arithmetic mean | 6.6 | 8.1 |
| CV% | 86.4 | 91.1 | |
| Glucuronide conjugate | |||
| Ae% (% of dose) | Arithmetic mean | 59.8 | 78.4 |
| CV% | 15.1 | 14.6 | |
| Unchanged edaravone and metabolites combined | |||
| Ae% (% of dose) | Arithmetic mean | 67.0 | 87.3 |
| CV% | 12.5 | 10.8 | |
Ae%, urinary excretion ratio of drug from time 0 to 48 hours; CLr, renal clearance; CV%, coefficient of variation percentage; IV= intravenous; L/h= litres per hour; PK= pharmacokinetic.
Study MT-1186-J03 Clinical Study Report (CSR)
| Adverse events | MT-1186-J03a PO (N = 42) | MT-1186-J03a IV (N = 42) |
|---|---|---|
| Patients with at least 1 adverse event | ||
| n (%) | 1 (2.4) | 1 (2.4) |
| Constipation, n (%) | 1 (2.4) | 0 (0) |
| Increased aspartate aminotransferase | 0 (0) | 1 (2.4) |
| Patients with at least 1 serious adverse event | ||
| n (%) | 0 (0) | 0 (0) |
| Patients who stopped treatment due to adverse events | ||
| n (%) | 0 (0) | 0 (0) |
IV= intravenous; PO= by mouth, oral administration
Study MT-1186-J03 Clinical Study Report (CSR)
| Plasma PK parametera | Geometric LS Mean | Ratio (PO/IV) | |
|---|---|---|---|
| PO | IV | (90% CI) | |
| Confirmatory PK parameters | |||
| Cmax (ng/mL) | 1500 | 1232 | 1.217 (1.090 – 1.359) |
| AUC0-t (ng·h/mL) | 1645 | 1689 | 0.974 (0.914 – 1.038) |
| AUC0-∞ (ng·h/mL) | 1665 | 1704 | 0.977 (0.917 – 1.041) |
| Reference PK parameters | |||
| tmax (h) | 0.44 | 1.00 | -0.559 (−0.604 – −0.513) |
| AUCall (ng·h/mL) | 1656 | 1697 | 0.976 (0.917 – 1.039) |
| MRT0-∞ (h) | 2.370 | 2.228 | 1.064 (0.970 – 1.1167) |
| Kel (I/h) | 0.0933 | 0.0998 | 0.935 (0.758 – 1.153) |
AUC0-t= area under the plasma concentration-time curve from zero up to the last quantifiable concentration time-point; AUC0-∞= area under the plasma concentration-time curve from zero up to infinity with extrapolation of the terminal phase; AUCall= area under the plasma concentration-time curve for all time-points; CI= confidence interval; Cmax= maximum plasma concentration after administration; IV= intravenous; Kel= elimination rate constant from the central compartment; LS= least square; MRT0-∞ = mean residence time from zero up to infinity; PK= pharmacokinetic; PO=by mouth, oral administration; tmax= time to reach Cmax
Study MT-1186-J03 Clinical Study Report (CSR)
| Characteristics | MT-1186-A01j |
|---|---|
| Designs and populations | |
| Study design | Phase 3, global, multi-center, open-label study to evaluate the long-term safety and tolerability of oral edaravone in subjects with ALS |
| Locations | 50 sites in Japan, the US, Canada, Germany, France and Italy |
| Patient enrolment dates | Study period:
|
| Randomized (N) | 185 |
| Inclusion criteria |
|
| Exclusion criteria | Exclusions Related to General Health or Concomitant Conditions:
|
| Drugs | |
| Intervention | Edaravone oral suspension,105 mg |
| Comparator(s) | N/A |
| Duration | |
| Phase | |
| Run-in | N/A |
| Double-blind | N/A |
| Follow-up | 24 weeks |
| Outcomes | |
| Primary end point | The primary endpoints evaluated were the safety and tolerability of edaravone that included the following safety assessments:
|
| Secondary and exploratory end points | Exploratory endpoints included functional and survival assessments of oral edaravone efficacy using the following:
|
| Notes | |
| Publications | N/A |
ADRs= adverse drug reactions; AEs= adverse events; ALSFRS-R= ALS Functional Rating Scale- Revised; ALT= alanine aminotransferase; AST= aspartate aminotransferase; C-SSRS= Columbia- Suicide Severity Rating Scale ; ECG= electrocardiogram; GFR= glomerular filtration rate; FVC= forced vital capacity; ICF= informed consent form; TEAEs= treatment-emergent adverse reactions; ULN= upper limit of normal
Study MT-1186-A01 Week 24 Clinical Study Report (CSR)
| Characteristic | MT-1186 -A01j 105 mg (2 Weeks On/Off) |
|---|---|
| Gender, n (%) | |
| Male | 119 (64.3) |
| Female | 66 (35.7) |
| Race, n (%) | |
| White | 108 (58.4) |
| Black or African American | 3 (1.6) |
| Asian – Japanese | 65 (35.1) |
| Asian – Not Japanese | 4 (2.2) |
| Not Reported | 5 (2.7) |
| Age (year) | |
| n | 185 |
| Mean | 59.9 |
| SD | 9.9 |
| Median (Min, Max) | 61 (22, 75) |
| Age category, n (%) | |
| 20 – 29 Years | 1 (0.5) |
| 30 – 39 Years | 6 (3.2) |
| 40 – 49 Years | 19 (10.3) |
| 50 – 59 Years | 60 (32.4) |
| 60 – 69 Years | 63 (34.1) |
| 370 Years | 36 (19.5) |
| <65 Years | 120 (64.9) |
| 365 Years | 65 (35.1) |
| Height (cm) | |
| n | 185 |
| Mean | 168.86 |
| SD | 10.24 |
| Median (Min, Max) | 169.50 (140.2, 193.0) |
| Body weight (kg) | |
| n | 185 |
| Mean | 71.56 |
| SD | 16.87 |
| Median (Min, Max) | 69.50 (33.9, 120.0) |
| Body Mass Index (BMI, kg/m2) | |
| n | 185 |
| Mean | 24.95 |
| SD | 4.61 |
| Median (Min, Max) | 24.21 (13.5, 43.4) |
| Country, n (%) | |
| United States | 71 (38.4) |
| Canada | 23 (12.4) |
| Germany | 6 (3.2) |
| France | 11 (5.9) |
| Italy | 9 (4.9) |
| Japan | 65 (35.1) |
| Region, n (%) | |
| North America – NA (United States, Canada) | 94 (50.8) |
| Western Europe – WE (Germany, France, and Italy) | 26 (14.1) |
| Japan – JP | 65 (35.1) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 3 (1.6) |
| Not Hispanic or Latino | 177 (95.7) |
| Not reported | 3 (1.6) |
| Unknown | 2 (1.1) |
BMI= body mass index; JP= Japan; NA=North America; SD= standard deviation; WE= Western Europe
Study MT-1186-A01 Week 24 Clinical Study Report (CSR)
| Characteristics | MT-1186-A01j 105 mg (2 Weeks On/Off) n (%) |
|---|---|
| Subjects screened | 216 |
| Screening failures Study entry criteria not met Withdrawal of consent COVID-19 | 31 (14.4) 25 (11.6) 2 (0.9) 4 (1.9) |
| Subjects enrolled to the study, Enrolled Population1 | 185 (85.6) |
| Subjects in Safety Analysis Population2 | 185 (100) |
| Subjects in PK Analysis Population2 | 39 (21.1) |
| Subjects who completed the 24-week period2 | 160 (86.5) |
| Subjects who discontinued during the 24-week period2 | 24 (13.0) |
| Primary reasons for discontinuation2 Adverse Event Death Withdrawal by subject Physician decision Other | 7 (3.8) 6 (3.2) 8 (4.3) 1 (0.5) 2 (1.1) |
Percentages are based on the number of screened patients.
Percentages are based on the number of enrolled patients.
Study MT-1186-A01 Week 24 Clinical Study Report (CSR).
| TEAEs | MT-1186-A01j 105 mg (2 Weeks On/Off) (N=185) | |
|---|---|---|
| Number of Subjects (%) | Number of Events | |
| Any TEAE | 146 (78.9) | 573 |
| Any TEAE related to study treatment | 36 (19.5) | 60 |
| Any severe TEAE | 17 (9.2) | 30 |
| Any TESAE | 21 (11.4) | 24 |
| Any TEAE leading to study treatment discontinuation | 11 (5.9) | 17 |
| Any TEAE leading to death | 6 (3.2) | 6 |
Study MT-1186-A01 Week 24 Clinical Study Report (CSR)
| System Organ Class Preferred Term | MT-1186-A01 105 mg (2 Weeks On/Off) (N=185) n (%) |
|---|---|
| Any TEAEs | 146 (78.9) |
| Nervous system disorders | 40 (21.6) |
| Headache | 11 (5.9) |
| Respiratory, thoracic, and mediastinal disorders | 32 (17.3) |
| Dyspnoea | 10 (5.4) |
| Gastrointestinal disorders | 48 (25.9) |
| Constipation | 13 (7.0) |
| Musculoskeletal and connective tissue disorders | 66 (35.7) |
| Back pain | 13 (7.0) |
| Muscular weakness | 30 (16.2) |
| General disorders and administration site conditions | 30 (16.2) |
| Fatigue | 14 (7.6) |
| Injury, poisoning, and procedural complications | 49 (26.5) |
| Fall | 29 (15.7) |
| Domain | Baseline | Week 4 | Week 12 | Week 24 |
|---|---|---|---|---|
| Bulbar function | ||||
| n | 185 | 182 | 179 | 169 |
| Mean | 10.6 | -0.1 | -0.6 | -0.9 |
| SD | 1.8 | 0.7 | 1.1 | 1.5 |
| Median | 11.0 | 0.0 | 0.0 | 0.0 |
| Min, max | 4, 12 | -3, 3 | -5, 3 | -7, 2 |
| LS mean1 | N/A | -0.2 | -0.7 | -1.1 |
| 95% CI1 | N/A | -0.4, −0.1 | -0.9, −0.4 | -1.4, −0.8 |
| Limb function | ||||
| n | 185 | 182 | 179 | 169 |
| Mean | 18.0 | -0.6 | -2.0 | -3.6 |
| SD | 3.7 | 1.3 | 2.5 | 3.6 |
| Median | 18.0 | 0.0 | -1.0 | -3.0 |
| Min, max | 6, 24 | -6, 3 | -17, 3 | -16, 3 |
| LS mean | N/A | -0.4 | -1.9 | -3.7 |
| 95% CI1 | N/A | -0.8, −0.1 | -2.3, −1.4 | -4.3, −3.0 |
| Fine motor function | ||||
| n | 185 | 182 | 179 | 169 |
| Mean | 9.1 | -0.3 | -1.1 | -1.8 |
| SD | 2.0 | 0.9 | 1.5 | 2.1 |
| Median | 9.0 | 0.0 | -1.0 | -1.0 |
| Min, max | 1, 12 | -4, 3 | -7, 3 | -8, 3 |
| LS mean1 | N/A | -0.2 | -1.0 | -1.8 |
| 95% CI1 | N/A | -0.4, 0.1 | -1.2, −0.7 | -2.2, −1.4 |
| Gross motor function | ||||
| n | 185 | 182 | 179 | 169 |
| Mean | 8.9 | -0.3 | -0.9 | -1.8 |
| SD | 2.4 | 0.8 | 1.4 | 2.0 |
| Median | 9.0 | 0.0 | -1.0 | -1.0 |
| Min, max | 3, 12 | -3, 2 | -10, 1 | -9, 2 |
| LS mean1 | N/A | -0.3 | -0.9 | -1.9 |
| 95% CI1 | N/A | -0.5, −0.1 | -1.2, −0.6 | -2.2, −1.5 |
| Respiratory function | ||||
| n | 185 | 182 | 179 | 168 |
| Mean | 11.4 | -0.1 | -0.4 | -0.6 |
| SD | 1.4 | 0.6 | 1.2 | 1.4 |
| Median | 12.0 | 0.0 | 0.0 | 0.0 |
| Min, max | 2, 12 | -2, 2 | -7, 3 | -7, 3 |
| LS mean1 | N/A | -0.1 | -0.5 | -0.8 |
| 95% CI1 | N/A | -0.3, 0.0 | -0.7, −0.2 | -1.0, −0.5 |
| Total score | ||||
| n | 185 | 182 | 179 | 168 |
| Mean | 40.0 | -0.8 | -2.9 | -5.2 |
| SD | 4.5 | 1.7 | 3.6 | 4.9 |
| Median | 41.0 | 0.0 | -2.0 | -4.0 |
| Min, max | 22, 48 | -9, 3 | -29, 3 | -20, 5 |
| LS mean1 | N/A | -0.8 | -3.0 | -5.6 |
| 95% CI1 | N/A | -1.3, −0.4 | -3.7, −2.4 | -6.5, −4.8 |
ALSFRS-R= Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; CI=confidence interval; LS mean= least-squares mean; MMRM= Mixed Model for Repeated Measures; N/A= not applicable; SD= standard deviation.
Statistics are from MMRM including the observed change from baseline as dependent variable and the ALSFRS-R at baseline, previous exposure to edaravone, concomitant riluzole, and visit at Week 4, 12, and 24 as fixed factors in the model.
Study MT-1186-A01 Week 24 Clinical Study Report (CSR)
| MT-1186 105 mg (2 Weeks On/Off) | |
|---|---|
| Number of events n (%) | |
| Death | 6 (3.2) |
| Tracheostomy | 0 (0.0) |
| Permanent Assisted Mechanical Ventilation | 0 (0.0) |
| Censored | 179 (96.8) |
| Generic name (brand name) | Strength | Dosage form | Price ($) | Recommended dosage regimen | Annual drug cost ($) | Difference in annual cost |
|---|---|---|---|---|---|---|
| Edaravone (oral Radicava) | 105 mg (5 mL) | Oral suspension | $9,200.0000a per 1 bottle of 1,050 mg (50 mL) $12,880.0000a per 2 bottles of 735 mg (35 mL) (Daily unit cost of $920.0000) | 105 mg (5 mL) taken orally or via a feeding tube (nasogastric tube or percutaneous endoscopic gastrostomy tube) according to the following schedule:b
| Initial year: $123,280c Subsequent years: $119,600c | — |
| Comparators | ||||||
| Edaravone (IV Radicava) | 30 mg (100 mL) | Solution for IV infusion | $920.0000d per two 30 mg bags | An IV infusion of 60 mg administered over a 60-minute period according to the following schedule:b
| Initial year: $123,280c Subsequent years: $119,600c | Initial year: $0 Subsequent years: $0 |
| Generic name (brand name) | Adverse event costs related to IV administration ($) | IV administration costs by site of infusion ($) | Method of infusion costs ($) | Aggregated health care cost per year ($) | Difference in health care costs per year ($) |
|---|---|---|---|---|---|
| Edaravone (oral Radicava) | 0 | 0 | 0 | 0 | NA |
| Comparator | |||||
| Edaravone (IV Radicava) | ||||||||| | ||||||||| | ||||||||| | ||||||||| | ||||||||| |
NA = not applicable.
Note: See Table 23 for further detail of these costs.
| Component cost | Edaravone oral | Edaravone IV | Incremental |
|---|---|---|---|
| Year 1 | |||
| Drug costs ($) | 123,280.00 | 123,280.00 | 0.00 |
| Administration costs ($) | 0.00 | 1,560.70 | –1,560.70 |
| Adverse event costs ($) | 0.00 | 88.57 | –88.57 |
| Total costs ($) | 123,280.00 | 124,929.27 | –1,649.27 |
| Subsequent years | |||
| Drug costs ($) | 119,600.00 | 119,600.00 | 0.00 |
| Administration costs ($) | 0.00 | 1,016.19 | –1,016.19 |
| Adverse event costs ($) | 0.00 | 88.57 | –88.57 |
| Total costs ($) | 119,600.00 | 120,704.76 | –1,104.76 |
| Health care resource | Percentage of patientsa | Frequency or number of administrations required per yearb | Unit cost | Treatment |
|---|---|---|---|---|
| Adverse event costs related to IV administrationc | ||||
| Infusion site thrombosis | Annual incidence: |||||d | $9,304e | Edaravone (IV RADICAVA®) | |
| IV-site infection | Annual incidence: |||||d | $9,878e | Edaravone (IV RADICAVA®) | |
| IV administration costs by site of infusion | ||||
| Clinic (operated by PSP) | ||||| | Initial year: ||||| Subsequent years: ||||| | $0f | Edaravone (IV RADICAVA®) |
| Home infusion (by visiting PSP nurse) | ||||| | $0f | Edaravone (IV RADICAVA®) | |
| Home infusion (self-infusion by patient/caregiver) | ||||| | $0g | Edaravone (IV RADICAVA®) | |
| Hospital | 0% | $70.56h | Edaravone (IV RADICAVA®) | |
| Long-term care facility | 0% | $70.56h | Edaravone (IV RADICAVA®) | |
| Method of infusion costs (i.e., catheter insertion, maintenance, and removal costs)i | ||||
| Peripheral line IV insertion | ||||| | Initial year: ||||| Subsequent years: ||||| | $0j | Edaravone (IV RADICAVA®) |
| PICC line | ||||| | Initial year: ||||| Subsequent years: ||||| | $773k | Edaravone (IV RADICAVA®) |
| IV insertion | ||||
| IV maintenancel | Initial year: ||||| Subsequent years: ||||| | $23.52m | ||
| Implantable port IV insertion | ||||| | Initial year: ||||| Subsequent years: ||||| | $1,382.00k | Edaravone (IV RADICAVA®) |
PICC: peripherally inserted central catheter; PSP: patient support program; SAE: serious adverse event
The percentage (i.e., distribution) of patients by site of infusion and by method of infusion were calculated from an ongoing real-world evidence study of Canadian patients on IV Radicava through secondary use of data collected through the PSP. Percentages presented here are from preliminary interim analysis of 359 patients exposed to IV Radicava (data cut-off June 16,2021. Mitsubishi Tanabe Pharma Canada, MTP Patient Support Real-World Evidence interim analysis. Data on file). Percentages were normalized to sum to 100%.
Frequency assumes 364 days, equivalent to 13 28-day cycles.
Only costs to treat serious IV-related adverse events are considered.
The annual incidence of adverse events was estimated from serious adverse events (SAEs) reported from an ongoing real-world evidence study of Canadian patients on IV Radicava through secondary use of data collected through the PSP |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||. The annual incidence of each SAEs then was calculated as the total number of reported adverse events divided by the total person-years on IV Radicava.
Serious adverse events in the model were costed as an average hospital inpatient admission for the event derived from Ontario Case Costing Initiative. Cost per infusion site thrombosis event was estimated using the average hospital costs for inpatient admissions with diagnosis I828 (embolism and thrombosis of other specified veins). Cost per IV-site infection event was estimated using the average hospital costs for inpatient admissions with diagnosis A491 (streptococcal infection, unspecified site).29
Costs borne by manufacturer through the PSP, therefore, no costs to the public payer.
No costs to public payer.
Assumes 90 minutes of nursing care (60 minutes of treatment time and 15 minutes on either side of the administration to prepare both the medication and the patient and then to wrap up and clean up) at an average hourly rate (April 1, 2022) of $47.04 ($41.63 per hour plus 13% to account for benefits).30 Methodology is based on CADTH CDR Pharmacoeconomic Review Report of IV edaravone.31
Frequency of catheter insertion and maintenance were obtained from PSP. Maintenance of IV line is required only for PICC lines.
For patients who receive infusion at PSP clinic, home infusion (by visiting PSP nurse) or self-infusion, peripheral line insertion costs are borne by manufacturer through the PSP, therefore, no costs to the public payer. For patients who receive infusion at hospital or long-term care facility, peripheral line insertion and removal costs are assumed to be included in IV administration costs.
Cost derived from Ontario Case Costing Initiative· Procedure 1LS53GRLF:Implant int dev v cava PTA non tun CVC. Ambulatory procedure, 2017 to 18.for PICC line insertion. Procedure 1IS53LALF: Implant int dev v cava OA implant CVC w injection port. Ambulatory procedure, 2017 to 18. For implantable port insertion.29
Two visits required during off-cycle. Conducted by public-run clinics.
As there is lack of information in the literature to inform this cost, assume 30 minutes of nursing care at an average hourly rate (April 1, 2022) of $47.04 ($41.63 per hour plus 13% to account for benefits).30
Source: Sponsor’s submission.22
| Key take-aways of the budget impact analysis |
|---|
|
| Parameter |
Sponsor’s estimate
(Reported as Year 1 / Year 2 / Year 3 if appropriate) |
|---|---|
| Target population | |
| Population of Canada (excluding Quebec)a | 30,868,081 / 31,174,556 / 31,484,074 |
| Patients with ALS (Prevalence = 6.84 per 100,000)b | ||||| / ||||| / ||||| |
| Proportion of ALS patients using edaravone in reference scenarioc | 10.31% / 10.33% / 10.34% |
| Proportion of ALS patients using edaravone in new drug scenarioc | 12.21% / 13.66% / 15.21% |
| Proportion of patients reimbursed by public pland | |||||| |
| Proportion of patients adherent to edaravone treatmente | 100% |
| Number of patients publicly reimbursed for edaravone IV in base yearb | ||||| |
| Number of patients eligible for drug under review in reference scenario (edaravone-naive subset by year) | 115 / 116 / 117 (32 / 1 / 1) |
| Number of patients eligible for drug under review in new drug scenario (edaravone-naive subset by year) | 136 / 153 / 172 (53 / 18 / 19) |
| Market Uptake, reference scenario | |
| Edaravone IV | 100% / 100% / 100% |
| Market Uptake, new drug scenarioc | |
| Edaravone oral | 72.2% / 78.6% / 79.4% |
| Edaravone IV | 27.8% / 21.4% / 20.6% |
| Cost of treatment, per patient (Initial year of treatment / per year thereafter) | |
| Drug plan payer perspective | |
| Edaravone oralf | $123,280 / $119,600 |
| Edaravone IVg | $123,280 / $119,600 |
| Health care payer perspective | |
| Edaravone oralf | $123,280 / $119,600 |
| Edaravone IV,g peripheral line (13.5% of IV patients) | $123,280 / $119,600 |
| Edaravone IV,g PICC line (47.1% of IV patients)h | $125,438 / $121,758 |
| Edaravone IV,g implantable port (39.4% of IV patients)h | $124,662 / $119,600 |
ALS = amyotrophic lateral sclerosis; PICC = peripherally inserted central catheter.
cited as Mitsubishi Tanabe Pharma Corporation forecast, data on file.35
cited as Mitsubishi Tanabe Pharma Patient Support Database.36
Assumption.
At submitted price.22
At Ontario Drug Benefit Exceptional Access Program list price.34
| Stepped analysis | Sponsor’s value or assumption | CADTH value or assumption | |
|---|---|---|---|
| Corrections to sponsor’s base case | |||
| None. | — | — | |
| Changes to derive the CADTH base case | |||
| 1. NIHB Population (base year) | Total Population: 30,564,619 NIHB Population: 887,518 Ontario Population: 14,915,270 | Total Population: 29,826,786 NIHB Population: 805,330 Ontario Population: 14,794,293 | |
| 2. Uptake of edaravone in new drug scenario (Y1 / Y2 / Y3) | 12% / 14% / 15% | 15% / 20% / 25% | |
| 3. Proportion edaravone patients using the oral formulation (Y1 / Y2 / Y3) | Edaravone experienced: 72.2% / 78.6% / 79.4% Edaravone naive: 72.2% / 78.6% / 79.4% | Edaravone experienced: 80% / 95% / 95% Edaravone naive: 100% / 100% / 100% | |
| CADTH base case | 1 + 2 + 3 | ||
NIHB = Noninsured Health Benefits; Y = year.
| Stepped analysis | Three-year total | |
|---|---|---|
| Drug plan payer perspective | Drug plan payer perspective | Health care payer perspective |
| Submitted base case | $13,770,852 | $13,494,762 |
| CADTH reanalysis 1 – NIHB population | $13,438,423 | $13,169,785 |
| CADTH reanalysis 2 – Higher edaravone uptake | $39,667,691 | $39,447,893 |
| CADTH reanalysis 3 – Higher proportion using oral edaravone | $13,770,852 | $13,404,045 |
| CADTH base case | $38,710,109 | $38,359,198 |
BIA = budget impact analysis; NIHB = Noninsured Health Benefits.
| Stepped analysis | Scenario | Year 0 (current situation) | Year 1 | Year 2 | Year 3 | Three-year total |
|---|---|---|---|---|---|---|
| Drug plan payer perspective | ||||||
| Submitted base case | Reference | $9,926,800 | $13,810,271 | $13,862,150 | $14,018,506 | $41,690,927 |
| New drug | $9,926,800 | $16,407,562 | $18,383,910 | $20,670,307 | $55,461,779 | |
| Budget impact | $0 | $2,597,291 | $4,521,761 | $6,651,801 | $13,770,852 | |
| CADTH base case | Reference | $9,926,800 | $13,469,517 | $13,527,516 | $13,680,098 | $40,677,130 |
| New drug | $9,926,800 | $19,735,719 | $26,388,608 | $33,262,912 | $79,387,240 | |
| Budget impact | $0 | $6,266,202 | $12,861,092 | $19,582,815 | $38,710,109 | |
| CADTH Scenario A: reduced edaravone uptake | Reference | $9,926,800 | $13,469,517 | $13,527,516 | $13,680,098 | $40,677,130 |
| New drug | $9,926,800 | $15,727,487 | $21,110,887 | $26,610,330 | $63,448,704 | |
| Budget impact | $0 | $2,257,971 | $7,583,370 | $12,930,232 | $22,771,573 | |
| CADTH Scenario B: 65% publicly reimbursed | Reference | $9,926,800 | $16,716,845 | $16,716,512 | $16,905,063 | $50,338,421 |
| New drug | $12,266,958 | $24,388,246 | $32,609,497 | $41,104,359 | $98,102,102 | |
| Budget impact | $2,340,158 | $7,671,401 | $15,892,984 | $24,199,296 | $47,763,681 | |
| Health care payer perspective | ||||||
| Submitted health care payer scenario | Reference | $10,018,495 | $13,953,921 | $13,990,150 | $14,147,952 | $42,092,023 |
| New drug | $10,018,495 | $16,457,157 | $18,420,123 | $20,709,505 | $55,586,785 | |
| Budget impact | $0 | $2,503,236 | $4,429,973 | $6,561,554 | $13,494,762 | |
| CADTH health care payer scenario | Reference | $10,018,495 | $13,608,607 | $13,652,427 | $13,806,419 | $41,067,453 |
| New drug | $10,018,495 | $19,754,058 | $26,397,588 | $33,275,004 | $79,426,651 | |
| Budget impact | $0 | $6,145,451 | $12,745,161 | $19,468,585 | $38,359,198 | |
| CADTH Scenario A: reduced edaravone uptake | Reference | $10,018,495 | $13,608,607 | $13,652,427 | $13,806,419 | $41,067,453 |
| New Drug | $10,018,495 | $15,745,826 | $21,118,070 | $26,620,003 | $63,483,900 | |
| Budget impact | $0 | $2,137,219 | $7,465,644 | $12,813,584 | $22,416,447 | |
| CADTH Scenario B: 65% publicly reimbursed | Reference | $10,018,495 | $16,899,379 | $16,870,869 | $17,061,164 | $50,831,413 |
| New Drug | $12,380,270 | $24,410,909 | $32,620,594 | $41,119,302 | $98,150,804 | |
| Budget impact | $2,361,775 | $7,511,529 | $15,749,724 | $24,058,138 | $47,319,391 | |
BIA = budget impact analysis. Note: A correction was made to the sponsor’s reported results ensuring the base year was not included in the 3-year total column.
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.
CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.
This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.
Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.
This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.
This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.
The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.
About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Sponsor: Mitsubishi Tanabe Pharma Canada, Inc.
Therapeutic area: Amyotrophic lateral sclerosis
Copyright © 2023 - Canadian Agency for Drugs and Technologies in Health. Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND).